N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

ABSTRACT

A novel class of inhibitors of protein kinates that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:

INCORPORATION BY REFERENCE

The following publication is referred to herein and its contents arehereby incorporated by reference in their entirety:

International Patent Application No PCT/GB2013/050982 (WO 2013/156780)titled “Therapeutic compounds” in the name of Changzhou Le SunPharmaceuticals Limited.

TECHNICAL FIELD

The present invention relates to a novel class of inhibitors of proteinkinases useful in the treatment of proliferative cell diseases andconditions including cancers.

PRIORITY DOCUMENT

The present application claims priority from Australian ProvisionalPatent Application No 2015903106 titled “Novel kinase inhibitors H”filed on 4 August 2015, the content of which is hereby incorporated byreference in its entirety.

BACKGROUND

There is an ongoing need to identify and develop new compounds fortreating proliferative diseases and conditions including cancers. Amongthe numerous “targets” for potential anti-proliferative compounds underinvestigation are the group of enzymes known as protein kinases.

Cyclin-dependent kinases (CDKs) are a type of protein kinase. They areknown to be associated with various cyclin subunits, playing pivotalroles in the regulation of a variety of important regulatory pathways incells, including cell-cycle control, apoptosis, neuronal physiology,differentiation and transcription. There are more than 20 CDKs which maybe classified into two major groups, reflecting their functions; namely,the cell cycle regulator CDKs and the transcription regulator CDKs. Theclass of the cell cycle regulator CDKs includes CDK1, CDK2, CDK3, CDK4and CDK6, and Urey function with their cyclin partners (eg cyclin A, B,D1, D2, D3, E and F) to regulate promotion of the cell cycle. The classof the transcription regulator CDKs includes CDK7, CDK8, CDK9 and CDK11, which work together with cyclin C, H, K, L1, L2, T1 and T2 and tendto play roles in transcriptional regulation. Given the functions ofthese two CDK classes, it is perhaps not surprising that CDKs have beenimplicated in cell proliferation diseases and conditions, particularlycancer. Cell proliferation is a result of the direct or indirectderegulation of the cell division cycle and the CDKs play a criticalrole in the regulation of the various phases of this cycle. Therefore,inhibitors of CDKs and their associated cyclins are considered to beuseful targets for cancer therapy.

Certain pyrimidine-based compounds have been previously investigated foruse in treating proliferative cell diseases and conditions includingcancers, for example. 4-thiazol-2-pyridinylamino-pyrimidines and5-substituted-4-thiazol-pyrimidines (see International patentpublications WO 2005/012298 and WO2013/156780, respectively). Thesecompounds inhibit multiple protein kinases, particularly CDKs, includingCDK1/cyclin B, CDK2/cyclin E, CDK2/cyclin A, CDK4/cyclin D1, CDK7/cyclinH and CDK9/cyclin T1.

The present applicant has now identified a new class ofthiazole-pyrimidine compounds for use in the prevention and/or treatmentof proliferative diseases and conditions including cancers. While notwishing to be bound by theory, it is considered that these novelcompounds are capable of inhibiting cell proliferation by inhibiting theactivity of CDK4 and/or CDK6.

SUMMARY

According to a first aspect of the present invention, there is provideda compound of formula I shown below.

wherein:z represents an optional bond such that the bond between N and theadjacent carbon atom can be a single or double bond;R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently selected from thegroup consisting of H₁alky;, alkyl-R¹⁰, aryl, aryl-R¹⁵, aralkyl,aralkyl-R¹¹, halogen, NO₂, CN, CF₃, OH, O-alkyl, COR¹⁹, COOR¹⁹, O-aryl,O-R¹⁹, NH₂, NH-alkyl. NH-aryl, N-(alkyl)₂, N-(aryl)₂, N-(alkyl)(aryl),NH-R¹⁰, N-(R¹⁰)(R¹¹), N-(alkyl)(R¹⁰), N-(aryl)(R¹⁰), SH-alkyl, SH-aryl,S-(alkyl)₂, S-(aryl)₂, S-(alkyl)(aryl), S-R¹⁰, S-(R¹⁰)(R¹¹),S-(alkyl)(R¹⁰), S-(aryl)(R¹⁰), COOH, CONH₂, CONH-alkyl, CONH-aryl,CON-(alkyl)(R¹⁰), CON(aryl)(R¹⁰), CONH-R¹⁰, CON-(R¹⁰)(R¹¹), SO₃H,SO₂-alkyl, SO₂-alkyl-R¹⁰, SO₂-aryl, SO₂-aryl-R¹⁰, SO₂NH₂, SO₂N-R¹⁰,SO₂N-(R¹⁰)(R¹¹), CF₃, CO-alkyl, CO-alkyl-R¹⁰, CO-aryl, CO-aryl-R¹⁰ andR¹²,wherein said alkyl, aryl and aralkyl groups may be optionallysubstituted with one or more groups selected from halogen, CN, OH,O-methyl, NH₃, COOH, CONH₂ and CF₃.and wherein when bond z is absent, R¹ is taken together with R⁸ and is═O or ═S;R⁸ is together with R⁸ ═O or ═S when bond z is absent, or is not presentwhen bond z is present;R⁹ is H, alkyl, aryl or heterocyclic group when bond z is absent, or isnot present when bond z is present;andR¹⁰, R¹¹ and R¹² are independently selected from water solubilisinggroups;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

In a second aspect, tire present invention provides the use of acompound as defined in the first aspect or a pharmaceutically acceptablesalt, solvate or prodrug thereof, for treating cancer or anotherproliferative cell disease or condition.

In a third aspect, the present invention provides a method of treatingcancer or another proliferative cell disease or condition in a subject,the method comprising administering to said subject a therapeuticallyeffective amount of a compound as defined in the first aspect or apharmaceutically acceptable salt, solvate or prodrug thereof, optionallyin combination with a pharmaceutically acceptable carrier, diluentand/or excipient.

In a fourth aspect, the present invention provides the use of a compoundas defined in the first aspect, or a pharmaceutically acceptable salt,solvate or prodrug thereof, in the manufacture of a medicament fortreating cancer or another proliferative cell disease or condition.

In a fifth aspect, the present invention provides a pharmaceuticalcomposition or medicament comprising a compound as defined in the firstaspect and a pharmaceutically acceptable carrier, diluent and/orexcipient

In a sixth aspect, the present invention provides a method formodulating protein kinase activity in a cell, comprising introducing toor contacting said cell with an effective amount of a compound asdefined in the first aspect or a pharmaceutically acceptable salt,solvate or prodrug thereof.

BRIEF DESCRIPTION Of FIGURES

FIG. 1 provides graphical results of cell cycle analysis for arepresentative compound of the present invention (ie compound 60described herein), wherein cells of the acute myeloid leukaemic cellline MV4-11 were treated 60 for 24 hours at the concentrations shown and

FIG. 2 provides graphical results obtained from, an apoptotic assayusing a representative compound of the present invention (ie compound 47described herein), wherein MV4-11 cells were treated for 24. hours with47 at concentrations of 0.25 μM, 1.25 μM, 2.50 μM.

DETAILED DESCRIPTION

The present applicant has now identified a new class of4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives suitable for usein the prevention and/or treatment of proliferative cell diseases andconditions including cancers, which possess desirable biologicalactivity (eg the compounds may inhibit cell proliferation by inhibitingthe activity of CDK4 and/or CDK6),

In a first aspect, the present invention provides a compound of formulaI shown below:

wherein:z represents an optional bond such that the bond between N and theadjacent carbon atom can be a single or double bond;R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are each independently selected from thegroup consisting of H₁alky;, alkyl-R¹⁰, aryl, aryl-R¹⁵, aralkyl,aralkyl-R¹¹, halogen, NO₂, CN, CF₃, OH, O-alkyl, COR¹⁹, COOR¹⁹, O-aryl,O-R¹⁹, NH₂, NH-alkyl. NH-aryl, N-(alkyl)₂, N-(aryl)₂, N-(alkyl)(aryl),NH-R¹⁰, N-(R¹⁰)(R¹¹), N-(alkyl)(R¹⁰), N-(aryl)(R¹⁰), SH-alkyl, SH-aryl,S-(alkyl)₂, S-(aryl)₂, S-(alkyl)(aryl), S-R¹⁰, S-(R¹⁰)(R¹¹),S-(alkyl)(R¹⁰), S-(aryl)(R¹⁰), COOH, CONH₂, CONH-alkyl, CONH-aryl,CON-(alkyl)(R¹⁰), CON(aryl)(R¹⁰), CONH-R¹⁰, CON-(R¹⁰)(R¹¹), SO₃H,SO₂-alkyl, SO₂-alkyl-R¹⁰, SO₂-aryl, SO₂-aryl-R¹⁰, SO₂NH₂, SO₂N-R¹⁰,SO₂N-(R¹⁰)(R¹¹), CF₃, CO-alkyl, CO-alkyl-R¹⁰, CO-aryl, CO-aryl-R¹⁰ andR¹²,wherein said alkyl, aryl and aralkyl groups may be optionallysubstituted with one or more groups selected from halogen. CN, OH,O-methyl, NH₂, COOH, CONH₂ and CF₃,and wherein when bond z is absent, R¹ is taken together with R⁸ and is═O or ═S;R⁸ is together with R¹ ═O or ═S when bond z is absent, or is not presentwhen bond z is present;R⁹ is H, alkyl, aryl or heterocyclic group when bond z is absent, or isnot present when bond z is present;andR¹⁰, R¹¹ and R¹² are independently selected from water solubilisinggroups;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

In some embodiments, tire compounds of formula I may preferably compriseat least one water solubilising group R¹⁰, R¹¹ or R¹². That is, in suchembodiments, the compound is as defined above in paragraph [0018] withthe proviso that said compound comprises at least one of said R¹⁰, R¹¹and R¹² groups. The present applicant has found that notwithstanding theaddition of such solubilising group(s), the compounds possess desirablebiological activity (eg by inhibiting the activity of CDK4 and/or CDK6).The presence of at least one water solubilising group may enhance invivo absorption and oral bioavailability

The compounds of formula I have been found to possess antiproliferativeactivity and are therefore considered to be of use in the treatment ofproliferative cell diseases and conditions such as cancer, leukaemia,lymphoma and other diseases and conditions associated with uncontrolledcell proliferation (or, in other words, requites control of the cellcycle) such as, for example, some cardiovascular diseases or conditionssuch as restenosis and cardiomyopathy, some auto-immune diseases such asglomerulonephritis and rheumatoid arthritis, dermatological conditionssuch as psoriasis, and fungal or parasitic disorders. As used herein, ananti-proliferative effect within the scope of the present invention maybe demonstrated by the ability to inhibit cell proliferation in an invitro whole cell assay. These assays, including methods for theirperformance, are described in more detail in the examples providedhereinafter.

The compounds of formula I may inhibit any of the steps or stages in thecell cycle, for example, formation of the nuclear envelope, exit fromthe quiescent phase of the cell cycle (G0), G1 progression, chromosomedecondensation, nuclear envelope breakdown, START, initiation of DNAreplication, progression of DNA replication, termination of DNAreplication, centrosome duplication. G2 progression, activation ofmitotic or meiotic functions, chromosome condensation, centrosomeseparation, microtubule nucleation, spindle formation and function,interactions with microtubule motor proteins, chromatid separation andsegregation, inactivation of mitotic functions, formation of contractilering, and cytokinesis functions. In particular, the compounds of formulaI may influence certain gene functions such as chromatin binding,formation of replication complexes, replication licensing,phosphorylation or other secondary modification activity, proteolyticdegradation, microtubule binding, actin binding, septin binding,microtubule organising centre nucleation activity and binding tocomponents of cell cycle signalling pathways.

Thus, in a second aspect, the present invention provides the use of acompound as defined in the first aspect or a pharmaceutically acceptablesalt, solvate or prodrug thereof, for treating cancer or anotherproliferative cell disease or condition.

In a third aspect, the present invention provides a method of treatingcancer or another proliferative cell disease or condition in a subject,the method comprising administering to said subject a therapeuticallyeffective amount of a compound as defined in the first aspect or apharmaceutically acceptable salt, solvate or prodrug thereof, optionallyin combination with a pharmaceutically acceptable carrier, diluentand/or excipient

In a fourth aspect, the present invention provides the use of a compoundas defined in the first aspect, or a pharmaceutically acceptable salt,solvate or prodrug thereof, in the manufacture of a medicament fortreating cancer or another proliferative cell disease or condition.

In a fifth aspect, the present invention provides a pharmaceuticalcomposition or medicament comprising a compound as defined in the firstaspect and a pharmaceutically acceptable carrier, diluent and/orexcipient

In a sixth aspect, the present invention provides a method formodulating protein kinase activity in a cell, comprising introducing toor contacting said cell with an effective amount of a compound asdefined in the first aspect or a pharmaceutically acceptable salt,solvate or prodrug thereof.

In this specification, a number of terms are used which are well knownto those skilled in the art. Nevertheless, for the purposes of clarity,a number of these terms are hereinafter defined.

As used herein, the term “treating” includes prophylaxis as well as thealleviation of established symptoms of a condition. As such, the act of“treating” a disease or condition therefore includes: (1) preventing ordelaying the appearance of clinical symptoms of the disease or conditiondeveloping in a subject afflicted with or predisposed to the disease orcondition; (2) inhibiting the disease or condition (ie arresting,reducing or delaying the development of the disease or condition or arelapse thereof (in case of a maintenance treatment) or at least oneclinical or subclinical symptom thereof; and (3) relieving orattenuating the disease or condition (ie causing regression of thedisease or condition or at least one of its clinical or subclinicalsymptoms).

As used herein, the term “alkyl” includes both straight chain andbranched alkyl groups having from 1 to 8 carbon atoms (eg methyl, ethylpropyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl etc).

As used herein, the term “aryl” refers to a substituted (mono- or poly-)or unsubstituted monoaromatic or polyaromatic group, wherein saidpolyaromatic group may be fused or unfused. The term therefore includesgroups having from 6 to 10 carbon atoms (eg phenyl, naphthyl etc). It isalso to be understood that the term “aryl” is synonymous with the term“aromatic”.

As used herein, the term “aralkyl” is used as a conjunction of the termsalkyl and aryl as defined above.

As used herein, the term “alicyclic” refers to a cyclic aliphatic group.

The term “aliphatic” takes its normal meaning in the art and includesnon-aromatic groups such as alkanes, alkenes and alkynes and substitutedderivatives thereof.

The term “halogen” refers to fluoro, chloro, bromo and iodo

As used herein, the term “heterocyclic” refers to a saturated orunsaturated cyclic group comprising one or more heteroatoms in the ring.

The term “derivative” as used herein, includes any chemical modificationof an entity, Illustrative of such chemical modifications is thereplacement of hydrogen by a halogen group, an alkyl group, an acylgroup or an amino group.

As used herein, the phrase “manufacture of a medicament” includes theuse of one or more of the compounds of formula I directly as themedicament or in any stage of the manufacture of a medicament comprisingone or more of the compounds of formula I.

Some of the compounds of formula I may exist as single stereoisomers,racemates, and/or mixtures of enantiomers and/or diastereomers. All suchsingle stereoisomers, racemates and mixtures thereof, are encompassedwithin the scope of the present invention. The isomeric forms such asdiastereomers, enantiomers, and geometrical isomers can be separated byphysical and/or chemical methods known to those skilled in the art.

The term “pharmaceutically acceptable salt” as used herein, refers tosalts that retain the desired biological activity of the compounds offormula I, and include pharmaceutically acceptable acid addition saltsand base addition salts. Suitable pharmaceutically acceptable acidaddition salts of the compounds of formula I may be prepared from aninorganic acid or from an organic acid. Examples of such inorganic acidsare hydrochloric, sulfuric and phosphoric acid. Appropriate organicacids may be selected from aliphatic, cycloaliphatic, aromatic,heterocyclic carboxylic and sulfonic classes of organic acids, examplesof which are formic, acetic, propionic, succinic, glycolic, gluconic,lactic, malic, tartaric, citric, fumaric. maleic, alkyl sulfonic andarylsulfonic. Additional information on pharmaceutically acceptablesalts can be found in Remington's Pharmaceutical Sciences. 19th Edition.Mack Publishing Co., Easton. Pa. 1995.

In the case of compounds of formula I that are solid, it will beunderstood by those skilled in the art that the compounds (orpharmaceutically acceptable salts, solvates or prodrugs thereof) mayexist in different crystalline or polymorphic forms, all of which areencompassed within the scope of the present invention.

“Prodrug” means a compound that undergoes conversion to a compound offormula I within a biological system, usually by metabolic means (eg byhydrolysis, reduction or oxidation). For example, an ester prodrug of acompound of formula I containing a hydroxyl group may be convertible byhydrolysis in vivo to the compound of formula I. Suitable esters of thecompounds of formula I containing a hydroxyl group may be, for example,acetates, citrates, lactates, tartrates, malonates, oxalates,salicylates, propionates, succinates, fumarates, maleates,methylene-bis-P-hydroxynaphthoates, gestisates, isethionates,di-p-toluoyltartrates, methanesulfonates, ethanesulfonates,benzenesulfonates, p-toluensulfonates, cyclohexylsulfanates andquinates. As another example, an ester prodrug of a compound of formulaI containing a carboxy group may be convertible by hydrolysis in vivo tothe compound of formula I. Examples of ester prodrugs include thosedescribed by Leinweber F J, Drug Metab Rev 18:379-439 (1987). Similarly,an acyl prodrug of a compound of formula I containing an amino group maybe convertible by hydrolysis in vivo to the compound of formula I.Examples of prodrugs for these and other functional groups, includingamines, are provided in Prodrugs: challenges and rewards. Valentino JStella (ed). Springer, 2007.

The term “therapeutically effective amount” or “effective amount” is anamount sufficient to effect beneficial or desired clinical results. Atherapeutically effective amount can be administered in one or moreadministrations. Typically, a therapeutically effective amount issufficient for treating a disease or condition or otherwise to palliate,ameliorate, stabilise, reverse, slow or delay the progression of adisease or condition such as, for example, cancer or anotherproliferative cell disease or condition. By way of example only, atherapeutically effective amount of a compound of formula I, or apharmaceutically acceptable salt, solvate or prodrug thereof, maycomprise between about 0.1 and about 250 mg/kg body weight per day, morepreferably between about 0.1 and about 100 mg/kg body weight per dayand, still more preferably between about 0.1 and about 25 mg/kg bodyweight per day. However, notwithstanding the above, it will beunderstood by those skilled in the art that the therapeuticallyeffective amount may vary and depend upon a variety of factors includingthe activity of the particular compound (or salt, solvate or prodrugthereof), the metabolic stability and length of action of the particularcompound (or salt, solvate or prodrug thereof), the age, body weight,sex, health, route and time of administration, rate of excretion of theparticular compound (or salt, solvate or prodrug thereof), and theseverity of, for example, the cancel of other proliferative cell diseaseor condition to be treated.

The compounds of formula I, and pharmaceutically acceptable salts,solvates and prodrugs thereof, are capable of inhibiting proteinkinases, especially CDKs and may show higher selectivity (to inhibit)CDK4 and/or CDK6 over other protein kinases As mentioned above, CDK4 andCDK6 promote cancer cell proliferation. As such, the compounds offormula I, and pharmaceutically acceptable salts, solvates and prodrugsthereof, which are believed to inhibit CDK4 and/or CDK6, have utility inboth in vitro and in vivo applications (eg in vitro cell-based assays)and as the basis of a therapeutic method of treating cancer or anotherproliferative cell disease or condition in a subject.

The compounds of formula I bear a thiazole group attached to thepyrimidine ring through one of the ring carbon atoms (particularly, firecarbon at position 4).

The compounds of formula I may bear at least one water solubilisinggroup (eg provided by R¹⁰, R¹¹ and/or R¹²). The term “water solubilisinggroup” will be well understood by those skilled in the art as referringto any polar functional group which either ionises or is capable offorming hydrogen bonds with water molecules to increase the watersolubility of the compound (ie relative to the water solubility of thecorresponding compound lacking the water solubilising group). Examplesof suitable water solubilising groups and methods and considerations fortheir introduction are described in, for example, Fundamentals ofMedicinal Chemistry by Gareth Thomas (publisher: John Wiley & Sons).

Preferably, where present. R¹⁰ and R¹¹ are independently selected fromwater solubilising groups of the group consisting of:

-   -   i) mono-, di- and poly-hydroxylated alicyclic groups, di- or        poly-hydroxylated aliphatic or aryl groups, N-, O- and/or        S-containing heterocyclic groups substituted with one or more        hydroxyl or ammo groups, aliphatic and aryl groups comprising        one or more carboxamide, sulfoxide, sulfone or sulfonamide        groups, and halogenated alkylcarbonyl groups; and    -   (ii) COOH, SO₃H, OSO₃H. PO₃H₂ and OPO₃H₂.

Preferably, where present, R¹² is selected from water solubilisinggroups of the group consisting of:

-   -   i) mono-, di and poly-hydroxylated alicyclic groups, di- or        poly-hydroxylated aliphatic or aryl groups; N-, O- and/or        S-containing heterocyclic groups substituted with one or more        hydroxyl or amino groups, aliphatic and aryl groups comprising        one or more carboxamide, sulfoxide, sulfone or sulfonamide        groups, and halogenated alkylcarbonyl groups;    -   (ii) COOH, SO₃H, OSO₃H, PO₃H₂ and OPO₃H₂;    -   (iii) NHCO(CH₂)_(m)[NHCO(CH₂)_(m′)]_(p)[NHCO(CH₂)_(m″)]_(q)Y and        NHCO(CH₂)_(t)NH(CH₂)_(t′)Y wherein p and q are each        independently selected from integers 0 or 1, and m, m′, m″, t        and ′ are each independently selected from integers 1 to 10, and        Y is selected from:    -   (a) alicyclic, aryl and heterocyclic groups comprising one or        more O-, S- or N- heteroatoms, which may further comprise an        alkyl bridge (eg a —CH₂— or —CH₂CH₂— bridge),    -   (b) alicyclic groups comprising one or more of —O—, NH₂, —NH—,        ═N—, quaternary amine salt, and amidine, and    -   (c) morpholine, piperazine or 1,4-diazepane groups, each of        which may be optionally substituted by one or more substituents        selected from SO₂-alkyl, alkyl optionally substituted by one or        more OH groups, CO-alkyl, aralkyl COO-alkyl, and an ether group        optionally substituted by one or more OH groups;    -   (iv) (CH₂)_(n)NR¹³COR¹⁴, (CH₂)_(n′)NR¹³SO₂R¹⁴ and SO₂R₁₅,        wherein R¹³ is selected from H and alkyl, R¹⁴ and R¹⁵ are each        independently selected from alkyl groups optionally comprising        one or more heteroatoms and/or optionally substituted with one        or more substituents independently selected from OH, NH₂,        halogen and NO₂, and n and n′ are each independently selected        from integers 0, 1, 2 and 3;    -   (v) ether and polyether groups optionally substituted with one        or more OH groups or one or more Y groups, wherein Y is as        defined above at (iii):    -   (vi) (CH₂)_(r)NH₂, wherein r is selected from integers 0, 1, 2        and 3;    -   (vii) (CH₂)_(r)OH, wherein r′ is selected from integers 0, 1, 2        and 3;    -   (viii) (CH₂)_(n″)NR¹⁶COR¹⁷, wherein R¹⁶ is H or alkyl, n″ is        selected from integers 0, 1, 2 and 3, and R¹⁷ is an aryl group        optionally substituted with one or more substituents selected        from halogen, NC₂, OH, alkoxy NH₂, COOH, CONH₂ and CF₃; and    -   (ix) SO₂NR¹⁸R¹⁹, wherein R¹⁸ and R¹⁹ are each independently        selected from H, alkyl and aryl, with the proviso that at least        one of R¹⁸ and R¹⁹ is other than H, or R¹⁸ and R¹⁹ together form        a cyclic group optionally comprising one or more heteroatoms        selected from N, O and S, and wherein said alkyl, aryl or cyclic        group is optionally substituted by one or mote substituents        selected from halogen, NO₂, OH, alkoxy, NH₂, COOH, CONH₂ and        CF₃.

In some embodiments. the compound is of the formula II shown below:

wherein R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined above for formulaI.

In some embodiments, the compound is of the formula III shown below:

wherein R², R³, R⁴, R⁵, R⁶ and R⁷ are as defined above for formula I, R⁸is together with R¹ is ═O or ═S. and R⁹ is H, alkyl (eg a C₁₋₆ alkyl or,preferably, a C₁₋₃ alkyl such as methyl, ethyl and cyclopentyl), aryl orheterocyclic group.

In some embodiments, R¹ is H, alkyl (eg a C₁₋₆ alkyl or, preferably, aC₁₋₃ alkyl such as methyl, ethyl and C(CH₃)₂), aryl. NH-alkyl (eg aNH-C₁₋₆ alkyl such as NH(C₅H₉) (ie NH-cyclopentyl) or, preferably, aNH-C₁₋₃ alkyl such as NH-CH₃), N(alkyl)₂ (eg a N(C₁₋₆ alkyl)₂ such asN(C₅H₉)₂ or a N(C₁₋₃ alkyl)₂ such as N(CH₃)₂), NH-aryl, N-(alkyl)(aryl).SH-alkyl (eg a SH-C₁₋₆ alkyl or, preferably, a SH-C₁₋₃ alkyl such asSHCH₃ and SHC(CH₃)) or R¹². Where R¹ is R¹², preferably R¹² is a mono-,di- or poly-hydroxylated alicyclic group, or an N-, O- and/orS-containing heterocyclic group substituted with one or more hydroxyl oramino group.

In some embodiments. R² is H, alkyl (eg a C₁₋₆ alkyl or, preferably, aC₁₋₃ alkyl such as methyl and ethyl), aryl, CN, CF₃, NH₂, NH-alkyl (eg aNH-C₁₋₆ alkyl such as NH((C₅H₉) or, preferably, a NH-C₁₋₃ alkyl such asNH-CH₃), N-(alkyl)₂ (eg a N(C₁₋₆ alkyl)₂ such as N(C₅H₉)₂ or a N(C₁₋₃alkyl)₂ such as N(CH₃)₂), N-(alkyl)(aryl) or R¹². Where R² is R¹²,preferably R¹² is a mono-, di- or poly-hydroxylated alicyclic group, oran N-, O- and/or S-containing heterocyclic group substituted with one ormore hydroxyl or amino group.

In some embodiments, R³ is H, alkyl (eg a C₁₋₆ alkyl or, preferably, aC₁₋₃ alkyl such as methyl or ethyl), CN, or halogen (preferably F).

In some embodiments. R⁴ is H, O-alkyl (preferably, a C₁₋₆ alkoxy or,more preferably, a C₁₋₃ alkoxy such as methoxy or ethoxy) or halogen(preferably F).

In some embodiments, at least one of R⁵ and R⁶, but preferably R⁵ is R¹²wherein R¹² is preferably an N-, O- and/or S-containing heterocyclicgroup substituted with one or more hydroxyl, amino or alkoxy (eg —COCH₃)group. Preferably, the heteroatom(s) is/are N.

In some embodiments, where at least one of R⁵ and R⁶ is R¹², R¹² ispreferably selected from the

Optionally, the R¹² substituents shown in the preceding paragraph [0055]may further comprise an alkyl bridge (eg a —CH₂— or —CH₂CH₂— bridge) 10the carbon atom at position ⅘ of the pyridine/phenyl ring.

Where R⁵ is R¹², R⁶ is preferably H. Vice versa, where R⁶ is R¹², R⁵ ispreferably H.

In some embodiments. R⁷ is H.

In some embodiments, R⁵ is R¹² and R², R³, R⁴, R⁶ and R⁷ are eachindependently selected from H, alkyl (eg a C₁₋₆ alkyl or, preferably, aC₁₋₃ alkyl), aryl, alicyclic, heterocyclic, halogen, NO₂, CN, CF₃, OH,O-alkyl (eg a C₁₋₆ alkoxy or, more preferably, a C₁₋₃ alkoxy such asmethoxy or ethoxy), NH₂, NH-alkyl leg a NH-C₁₋₆ alkyl such as NH(C₅H₉)or, preferably, a NH-C₁₋₃ alkyl such as NH-CH₃) and N-(alkyl)₂ (eg aN(C₁₋₆ alkyl)₂ such as N(C₅H₉)₂ or a N(C₁₋₃ alkyl)₂ such as N(CH₃)₂).

In some embodiments, the compound is of formula II and R⁵ is R¹², R¹ isalkyl (eg a C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃ alkyl such asmethyl and ethyl), NH(alkyl) (eg a NH-C₁₋₆ alkyl or, preferably, aNH-C₁₋₃ alkyl), N(alkyl)₂ (eg a N(C₁₋₆ alkyl)₂ such as N(C₅H₉)₂ or aN(C₁₋₃ alkyl)₂ such as N(CH₃)₂), NH(aryl), O-alkyl (eg a C₁₋₆ alkoxy or,more preferably, a C₁₋₃ alkoxy), S-alkyl (eg a S-C₁₋₆ alkyl or a S-C₁₋₃alkyl) and NH₂ and R₂, R³, R⁴, R⁶ and R⁷ are each independently selectedfrom H, alkyl (eg a C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃ alkyl),halogen. CN, CF₃, O-alkyl (eg a C₁₋₆ alkoxy or, more preferably a C₁₋₃alkoxy), NH₂ and NH-alkyl (eg a NH-C₁₋₆ alkyl or, preferably, a NH-C₁₋₃alkyl).

In some embodiments, the compound is of formula II and R⁵ is R¹², R¹ isalkyl (eg a C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃ alkyl such asmethyl and ethyl), NH(alkyl) (eg a NH-C₁₋₆ alkyl or, preferably, aNH-C₁₋₃ alkyl), N(alkyl)₂ (eg a N(C₁₋₆ alkyl)₂ or, more preferably, aN(C₁₋₃ alkyl)₂). NH(aryl), O alkyl (eg a C₁₋₆ alkoxy or, morepreferably, a C₁₋₃ alkoxy), S-alkyl (eg a S-C₁₋₆ alkyl or, S-C₁₋₃ alkyl)and NH₂, R³ is selected from H, alkyl, halogen and CN, and R², R⁴, R⁶and R⁷ are each independently selected from H, alkyl (eg a C₁₋₆ alkylsuch as cyclopentyl or a C₁₋₃ alkyl), halogen, CN, CF₃, O-alkyl (eg aC₁₋₆ alkoxy or, more preferably, a C₁₋₃ alkoxy), NH₂ and NH-alkyl (eg aNH-C₁₋₆ alkyl or, preferably, a NH-C₁₋₃ alkyl).

In some embodiments, the compound is of formula III and R⁵ is R¹², andR², R³, R⁴, R⁶ and R⁷ are each independently selected from H, alkyl (ega C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃ alkyl), halogen, CN, CF₃,O-alkyl (eg a C₁₋₆ alkoxy or, more preferably, a C₁₋₃ alkoxy), NH₂ andNH-alkyl (eg a NH-C₁₋₆ alkyl or, preferably, a NH-C₁₋₃ alkyl).

In some embodiments, the compound is of formula III and R⁵ is R¹², R³ isselected from H, alkyl (eg a C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃alkyl), halogen and CN and R², R⁴, R⁶ and R⁷ are each independentlyselected from H, alkyl (eg a C₁₋₆ alkyl such as cyclopentyl or a C₁₋₃alkyl), halogen, CN, CF₃, O-alkyl (eg a C₁₋₆ alkoxy or, more preferably,a C₁₋₃ alkoxy), NH₂ and NH-alkyl (eg a NH-C₁₋₆ alkyl or, preferably, aNH-C₁₋₃ alkyl).

In some preferred embodiments, the compounds of the present inventionexhibit anti-proliferative activity in human cell lines, as measured bya standard cytotoxicity assay. Preferably, the compound exhibits an IC₅₀value of less than 5 μM, even more preferably less than 1 μM as measuredby the cell viability (MTT proliferation) assay described in Example 2hereinafter. More preferably still, the compound exhibits an IC₅₀ valueof less than 0.5 μM.

In some preferred embodiments, the compounds of the present inventioninhibit one or more protein kinases, as measured by any standard assaywell known to those skilled in the art. Preferably, the compoundexhibits an IC₅₀ value of less than 1 μM or less than 0.5 μM as measuredby the kinase assay described in Example 2 hereinafter, more preferablystill less than 0.1 μM.

Particular examples of compounds according to the first aspect are shownin Table 1 below.

TABLE 1 Chemical structure of selected compounds of the presentinvention No. Structure Name Mass 1.

1-(4-(6-((4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl) piperazin-1-yl)ethan-1-one 409.5 2.

4-(2,4-dimethylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 367.5 3.

4-(2,4-dimethylthiazol-5-yl)-N-(5- (4-methylpiperazin-1-yl))pyridin-2-yl)pyrimidin-2-amine 381.5 4.

4-(2,4-dimethylthiazol-5-yl)-2-((5- (piperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile 392.5 5.

4-(2,4-dimethylthiazol-5-yl)-2-((5- (4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile 406.5 6.

2-((5-(4-acetylpiperazin-1-yl)pyridin-2-yl)amino)-4-(2,4-dimethylthiazol-5-yl)pyrimidine-5-carbonitrile 434.5 7.

4-(2-ethyl-4-methylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 381.5 8.

4-(2-ethyl-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2- yl)pyrimidin-2-amine 395.5 9.

4-(2-ethyl-4-methylthiazol-5-yl)-N- (5-(4-ethylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 409.6 10.

1-(4-(6-((4-(2-ethyl-4-methylthiazol-5-yl)-pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one423.5 11.

1-(4-(6-((5-chloro-4-(2-ethyl-4- methylthiazol-5-yl)-pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 458.0 12.

4-(2-Ethyl-4-methylthiazol-5-yl)-N- (5-morpholinopyridin-2yl)pyrimidin-2-amine 382.5 13.

4-(2-isopropyl-4-methylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 395.5 14.

4-(2-isopropyl-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 409.6 15.

N-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)-4-(2-isopropyl-4-methylthiazol-5- yl)pyrimidin-2-amine 423.6 16.

1-(4-(6-((4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one437.6 17.

4-(2-isopropyl-4-methylthiazol-5-yl)- N-(5-morpholinopyridin-2yl)pyrimidin-2-amine 396.5 18.

N-(5-(4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2- amine 437.6 19.

4-(2-methoxy-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 397.5 20.

4-(4-methyl-2-(methylthio)thiazol-5-yl)-N-(5-4-piperazin-1-yl)pyridin-2- yl)pyrimidin-2-amine 399.5 21.

4-(4-methyl-2-(methylthio)thiazol-5-yl)-N-(5-4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine413.6 22.

1-(4-(6-((4-(4-methyl-2- (methylthio)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 441.6 23.

4-(2-(isopropylthio)-4-methylthiazol-5- yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine 427.6 24.

4-(2-(isopropylthio)-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl) pyridin-2-yl)pyrimidin-2-amine 441.625.

1-(4-(6-((4-(2-(isopropylthio)-4- methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 469.6 26.

N,4-dimethyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyridin-4-yl)thiazol-2-amine 382.5 27.

4-(4-methyl-2-(methylamino)thiazol-5-yl)-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile407.5 28.

5-(5-fluoro)-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine400.5 29.

N,4-dimethyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 396.5 30.

4-(4-methyl-2-(methylamino)thiazol- 5-yl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5- carbonitrile 421.5 31.

5-(5-fluoro)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine414.5 32.

5-(5-fluoro)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine428.5 33.

1-(4-(6-((4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piprazin-1- yl)ethane-1-one 424.5 34.

2-((5-(4-acetylpiperazin-1-yl)pyridin- 2-yl)amino)-4-(4-methyl-2-(methylamino)thiazol-5-yl) pyrimidine-5-carbonitrile 449.5 35.

1-(4-(6-((5-fluoro-4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 442.5 36.

N,4-dimethyl-5-(2-((5- morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 383.5 37.

4-(4-methyl-2-(methylamino)thiazol-5- yl)-2-((5-morpholinopyridin-2-yl)amino)pyrimidine-5-carbonitrile 408.5 38.

5-(5-fluoro-2-((5-morpholinopyridin- 2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine 401.5 39.

5-(2-((5-(4-benzylpiperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine 472.6 40.

2-((5-(4-benzylpiperazin-1-yl)pyridin- 2-yl)amino)-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidine- 5-carbonitrile 497.6 41.

5-(2-((4-(4-benzylpiperazin-1-yl) phenyl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine 471.6 42.

2-((4-(4-benzylpiperazin-1-yl) phenyl)amino)-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidine- 5-carbonitrile 496.6 43.

N,N,4-trimethyl-5-(2-((5-piperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine 396.5 44.

5-(5-fluoro-2-((5-piperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,N,4-trimethylthiazol-2-amine 414.5 45.

N,N,4-trimethyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine 410.5 46.

5-(5-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4- yl)-N,N,4-trimethylthiazol-2-amine428.5 47.

5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)N,4-dimethylthiazol-2-amine442.6 48.

1-(4-(6-((4-(2-(dimethylamino)-4- methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 438.6 49.

1-(4-(6-((4-(2-(dimethylamino)-4- methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-one 456.5 50.

5-(5-fluoro-2-((5-morpholinopyridin-2- yl)amino)pyrimidin-4-yl)-N,N,4-trimethylthiazol-2-amine 415.5 51.

5-(5-fluoro-2-((5-(piperidin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine 399.5 52.

5-(5-fluoro-2-((5-(4- methylsulfonyl)piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)- N,4-dimethylthiazol-2-amine 478.653.

5-(2-((5-(1,4-diazepan-1-yl) pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4- dimethylthiazol-2-amine 414.5 54.

5-(5-fluoro-2-(pyridin-2- ylamino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine 316.4 55.

N-isopropyl-4-methyl-5-(2-((5- piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine 410.5 56.

N-isopropyl-4-methyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 424.6 57.

1-(4-(6-((4-(2-(isopropylamino)-4- methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3yl)piperazin-1- yl)ethan-1-one 452.6 58.

N-isopropyl-4-methyl-5-(2-((5- morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 411.5 59.

5-(2-((5-(1,4-diazepan-1-yl) pyridin-2-yl)amino)pyrimidin-4-yl)-N-isopropyl-4-methylthiazol-2-amine 424.6 60.

N-cyclopentyl-4-methyl-5-(2-((5- piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine 436.6 61.

N-cyclopentyl-5-(5-fluoro-2-((5- piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4- yl)methylthiazol-2-amine 454.6 62.

N-cyclopentyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine 490.6 63.

N-cyclopentyl-4-methyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 450.6 64.

N-cyclopentyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4- (trifluoromethyl)thiazol-2-amine 468.6 65.

N-cyclopentyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4- (trifluoromethyl)thiazol-2-amine 504.6 66.

N-cyclopentyl-5-(2-((5-(4- ethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4- methylthiazol-2-amine 464.6 67.

N-cyclopentyl-5-(2-((5-(4- ethylpiperazin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4- methylthiazol-2-amine 482.6 68.

1-(4-(6-((4-(2-(cyclopentylamino)-4- (trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3- yl)piperazin-1-yl)ethan-1-one 478.669.

1-(4-(6-((4-(2-(cyclopentylamino)-4- (trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3- yl)piperazin-1-yl)ethan-1-one 496.670.

1-(4-(6-((4-(2-(cyclopentylamino)-4- (trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3- yl)piperazin-1-yl)ethan-1-one 532.671.

N-cyclopentyl-4-methyl-5-(2-((5- morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 437.6 72.

N-cyclopentyl-5-(2-((5- morpholinopyridin-2- yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine 455.6 73.

N-cyclopentyl-5-(2-((5- morpholinopyridin-2- yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine 491.5 74.

5-(2-((5-(4-aminopiperidin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2- amine 450.6 75.

N-cyclopentyl-4-methyl-5-(2-((5- piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 435.6 76.

5-(2-((5-(1,4-diazepan-1-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine 450.6 77.

N-cyclopentyl-4-methyl-5-(2-(pyridin-2-ylamino)pyrimidin-4-yl)thiazol-2- amine 514.7 78.

N-cyclopentyl-4-methyl-5-(2-(pyridin-2-ylamino)pyrimidin-4-yl)thiazol-2- amine 352.5 79.

4-(6-((4-(2-(cyclopentylamino)-4- (trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3- yl)piperazine-1-carbaldehyde 518.680.

N-cyclopentyl-5-(5-fluoro-2-((5-(4- (methylsulfonyl)piperazin-1-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine 496.7 81.

N-cyclopentyl-5-(5-fluoro-2-((5-(4- (methylsulfonyl)piperazin-1-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine 468.6 82.

N-cyclopentyl-5-(5-fluoro-2-((5-(4- (methylsulfonyl)piperazin-1-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine 532.6 83.

N-cyclopentyl-5-(2-((5-((4- ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4- methylthiazol-2-amine 478.7 84.

N-cyclopentyl-5-(2-((5-(4- ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4- methylthiazol-2-amine 496.6 85.

N-cyclopentyl-N,4-dimethyl-5-(2-((5- (piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 450.6 86.

N-cyclopentyl-N,4-dimethyl-5-(2-((5- (4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2- amine 464.6 87.

1-(4-(6-((4-(2- (cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)pyrimidin-2- yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one 492.6 88.

N,N-diclopentyl-4-methyl-5-(2-((5- (piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine 504.7 89.

4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4- yl)-N-phenylthiazol-2-amine 444.690.

4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4- yl)-N-phenylthiazol-2-amine 458.691.

N,4-dimethyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N- phenylthiazol-2-amine 472.6 92.

4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4- yl)thiazol-2(3H)-one 383.5 93.

3,4-dimethyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol- 2(3H)-one 397.5 94.

3-ethyl-4-methyl-5-(2-((5-(4- methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol- 2(3H)-one 411.5 95.

5-(2-((5-(4-acetylpiperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2(3H)-one 411.5 96.

3-cyclopentyl-4-methyl-5-(2-((5- (piperazin-1-yl)pyridin-2-amino)pyrimidin-4-yl)thiazol-2(3H)- one 437.6 97.

4-methyl-5-(2-((5-(piperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one 369.4 99.

2-(4-(6-((5-fluoro-4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-ol 444.5 100.

8-(6-((5-fluoro-4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)1,8- diazaspiro[4,5]decan-2-one 468.6 101.

2-(2-(4-(6-((5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethoxy)ethan-1-ol 488.6 102.

1-(2-((5-fluoro-4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)-7,8-dihydro-1,6- naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one 429.5 103.

1-(2-((4-(2-(cyclopentylamino)4- methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)-7,8- dihydro-1,6-naphthyridin-6(5H)-yl)-2-hydroxyethan-1-one 483.6 104.

2-(4-(6-((4-(2-(cyclopentylamino)4-methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1- yl)ethan-1-ol 498.6 105.

2-(4-(6-((5-fluoro-4-(4-methyl-2- (methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-1,8- diazaspiro[4,5]decan-2-one 468.6 106.

5-(5-fluoro-2-((5-(4- ((methylsulfonyl)methyl)piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)- N,4-dimethylthiazol-2-amine 491.6107.

5-(5-fluoro-2-((5-(4- ((methylsulfonyl)methyl)piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)- N,4-dimethylthiazol-2-amine 458.5108.

1-(4-(6-((4-(2-(cyclopentylamino)4- methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)- 2-hydroxyethan-1-one 494.6

The compounds (and pharmaceutically acceptable salts, solvates andprodrugs thereof) may be administered in combination with one or moreadditional agent(s) for the treatment of cancer or another proliferativedisease or condition. For example, the compounds may be used incombination with other anti-cancer agents in order to inhibit more thanone cancer signalling pathway simultaneously so as to make cancer cellsmore susceptible to anti-cancer therapies (eg treatments with otheranti-cancer agents, chemotherapy, radiotherapy or a combination thereof.As such, the compounds of formula I may be used in combination with oneor more of the following categories of anti-cancer agents:

-   -   other anti-proliferative/antineoplastic drugs and combinations        thereof, as used in medical oncology, such as alkylating agents        (eg cis-platin, oxaliplatin, carbopiatin, cyclophosphamide,        nitrogen mustard, melphalan, chlorambucil, busulphan,        temozolamide and nitrosoureas); antimetabolites (eg gemcitabine        and antifolates such as fluoropyrimidines like 5-fluorouracil        and tegafur, raltitrexed, methotrexate, cytosine arabinoside,        fludarabine and hydroxyurea); antitumour antibiotics (eg        anthracyclines such as adriamycin, bleomycin, doxorubicin,        daunomycin. epirubicin, idarubicin, mitomycin-C, dactinomycin        and mithramycin), antimitotic agents (eg vinca alkaloids such as        vincristine, vinblastine, vindesine and vinorelbine and raxoids        including taxol and taxotere and polokinase inhibitors), and        topoisomerase inhibitors (eg epipodophyllotoxins such as        etoposide and teniposide, amascrine, topotecan and        camptothecin);    -   cytostatic agents such as antioestrogens (eg tamoxifen,        fulvestrant, toremifene, raloxifene, droloxifene and        iodoxyfene), antiandrogens (eg bicalutamide, fluramide,        nilutamide and cyproterone acetate). LHRH antagonists or LHRH        agonists (eg goserelin, leuprorelin and buserelin), progestogens        (eg megestrol acetate), aromatase inhibitors (eg as anastrozole,        letrozole, vorazole and exemestane and inhibitors of        5α-reductase such as finasteride:    -   anti-invasion agents (eg c-Src kinase family inhibitors such as        4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline        (AZD0530; International Patent Publication No WO 01/94341),        N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide        (dasatinib) and bosutinib (SK1-606)), and metalloproteinase        inhibitors including marimastat, inhibitors of urokinase        plasminogen activator receptor function or antibodies to        heparanase;    -   inhibitors of growth factor function (eg growth factor        antibodies and growth factor receptor antibodies such as the        anti-erbB2 antibody trastuzumab (Herceptin™), the anti-EGFR        antibody panitumumab, the anti-erbB1 antibody cetuximab        (Erbitux, C225) and any growth factor or growth factor receptor        antibodies disclosed by Stern et al. Critical reviews in        oncology/haematology, 2005, Vol. 54, pp11-29). Such inhibitors        also include tyrosine kinase inhibitors such as inhibitors of        the epidermal growth factor family (eg EGFR family tyrosine        kinase inhibitors such as        N-(3-chloro-4-flurophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine(gefitinib,        ZD1839),        N-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine        (erlotinib, OSI-774) and        6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine(CI        1033), erbB2 tyrosine kinase inhibitors such as lapatinib);        inhibitors of the hepatocyte growth factor family; inhibitors of        the insulin growth factor family inhibitors of the        platelet-derived growth factor family such as imatinib and/or        nilotinib (AMN107); inhibitors of serins threonine kinases (eg        Ras/Raf signalling inhibitors such as farnesyl transferase        inhibitors including sorafenib (BAY 43-9006), tipifarnib        (R115777) and lonafarnib (SCH66336)), inhibitors of cell        signalling through MEK and/or AKT kinases, c-kit inhibitors, abl        kinase inhibitors. P13 kinase inhibitors. Plt3 kinase        inhibitors, CSF-IR kinase inhibitors, IGF receptor (insulin-like        growth (actor) kinase inhibitors; aurora kinase inhibitors (eg        AZD1152, PH739358. VX-680, MLN8054, R763, MP235, MP529, VX-528        and AX39459) and cyclin dependent kinase inhibitors such as CDK2        and/or CDK9 inhibitors;    -   antiangiogenic agents such as those which inhibit the effects of        vascular endothelial growth factor (eg the anti-vascular        endothelial cell growth factor antibody bevacizumab (Avastin™)        and VEGF receptor tyrosine kinase inhibitors such as vandetanib        (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib        (AG-013736), pazopanib (GW 786034) and        4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline        (AZD2171; Example 240 within International Patent Publication No        WO 00/47212), compounds such as those disclosed in International        Patent Publication Nos WO97/22596, WO 97/30035, WO 97/32856 and        WO 98/13354, and compounds that work by other mechanisms (eg        linomide, inhibitors of integrin avb3 function and angiostarin);    -   vascular damaging agents such as Combretastatin A4 and compounds        disclosed in International Patent Publication Nos WO 99/02166,        WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO        02/08213;    -   an endothelin receptor antagonist such as zibotentan (ZD4054) or        atrasentan;    -   antisense therapies such as those which are directed to the        targets listed above, such as ISIS 2503, an anti-ras antisense;    -   gene therapy approaches, including for example approaches to        replace aberrant genes such as aberrant p53 or aberrant BRCA1 or        BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches        such as those using cytosine deaminase, thymidine kinase or a        bacterial nitroreductase enzyme and approaches to increase        patient tolerance to chemotherapy or radiotherapy such as        multi-drug resistance gene therapy: and    -   immunotherapy approaches, including for example ex vivo and in        vivo approaches to increase the immunogenicity of patient tumour        cells, such as transfection with cytokines such as interleukin        2. interleukin 4 or granulocyte-macrophage colony stimulating        factor, approaches to decrease T-cell anergy, approaches using        transfected immune cells such as cytokine-transfected dendritic        cells, approaches using cytokine-transfected tumour cell lines        and approaches using anti-idiotypic antibodies.

Where used in combination with other anti-cancer agents, a compound ofthe present invention and the other anti-cancer agent can beadministered in the same pharmaceutical composition or in separatepharmaceutical compositions. If administered in separate pharmaceuticalcompositions, the compound and the other anti-cancer agent may beadministered simultaneously or sequentially in any order (eg withinseconds or minutes or even hours leg 2 to 48 hours)).

The present invention is typically applied to the treatment of cancer oranother proliferative cell disease or condition in a human subject.However, the subject may also be selected from, for example, livestockanimals (eg cows, horses, pigs, sheep and goats), companion animals (egdogs and cats) and exotic animals (eg non-human primates tigers,elephants etc).

Cancers and other proliferative cell diseases and conditions that may betreated in accordance with the present invention include biliary tractcancer, brain cancer (including glioblastomas and medulloblastomas),breast cancer, cervical cancer: choriocarcinoma, colonic cancer,endometrial cancer, oesophageal cancer, gastric cancer, haematologicalneoplasms (including acute lymphocytic leukemia (ALL)), chroniclymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), acutemyeloid leukaemia (AML), multiple myeloma, AIDS-associated leukemias andadult T-cell leukemia lymphoma, intraepithelial neoplasms (includingBowen's disease and Paget's disease), liver cancer, lung cancer,lymphomas (including Hodgkin's disease and lymphocytic lymphomas),neuroblastomas, oral cancer (including squamous cell carcinoma), ovariancancer (including those arising from epithelial cells, stromal cells,germ cells, and mesenchymal cells), pancreatic cancer, prostate cancer,colorectal cancer, sarcomas (including leiomyosarcoma, rhabdomyosarcoma,liposarcoma, fibrosarcoma, and osteosarcoma), skin cancer (includingmelanoma, Kaposi's sarcoma, basocellular cancer, and squamous cellcancer), testicular cancer (including germinal tumours such as seminoma,non-seminoma teratomas, and choriocarcinomas), stromal tumours, germcell tumours, thyroid cancer (including thyroid adenocarcinoma andmedullar carcinoma), and renal cancer (including adenocarcinoma andWilms' tumour).

In some embodiments, the compounds of the present invention are used totreat cancers characterised by over-expression of CDK4 and/or cyclin Dincluding, for example, lung cancer (Wu et al., J Transl Med 9:38(2011)), breast cancer (An et al., Am J Pathol 154(1):113-118 (1999)).cancers of the central nervous system (CNS) and colorectal cancer (Ikedaet al., Jap J Clin Med 54(4):1054-1059(1996). CDK4 and/or cyclin Dover-expression may be determined by, for example, assessing the amountof mRNA encoding CDK4 and/or cyclin D in a suitable sample using any ofthe techniques well known to those skilled in the art (eg quantitativeamplification techniques such as qPCR).

In some embodiments, the compounds of the present invention are used totreat cancers characterised by over-expression of CDK6 and/or cyclin Dincluding, for example, T-cell acute lymphoblastic leukemia (ALL),colorectal cancer and medullablastoma (reviewed in Tadesse et al., CellCycle 14(20):3220-30, 2015). CDK6 and/or cyclin D over-expression may bedetermined by, for example, assessing the amount of mRNA encoding CDK6and/or cyclin D in a suitable sample using any of the techniques wellknown to those skilled in the art (eg quantitative amplificationtechniques such as qPCR).

The compounds of the present invention may be formulated into apharmaceutical composition with a pharmaceutically acceptable carrier,diluent and/or excipient. Examples of suitable carriers and diluents arewell known to those skilled in the art, and are described in, forexample, Remington's Pharmaceutical Sciences. Mack Publishing Co.,Easton, Pa. 1995. Examples of suitable excipients for the variousdifferent forms of pharmaceutical compositions described herein may befound in the Handbook of Pharmaecutical Excipients. 2^(nd) Edition,(1994), Edited by A Wade and P J Weller. Examples of suitable carriersinclude lactose, starch, glucose, methyl cellulose, magnesium stearate,mannitol, sorbitol and the like. Examples of suitable diluents includeethanol, glycerol and water. The choice of carrier, diluent and/orexcipient may be made with regard to the intended route ofadministration and standard pharmaceutical practice.

A pharmaceutical composition comprising a compound of the presentinvention may further comprise any suitable binders, lubricants,suspending agents, coating agents and solubilising agents. Examples ofsuitable binders include starch, gelatin, natural sugars such asglucose, anhydrous lactose, free-flow lactose, beta-lactose, cornsweeteners, natural and synthetic gums, such as acacia, tragacanth orsodium alginate, carboxymethyl cellulose and polyethylene glycol.Examples of suitable lubricants include sodium oleate, sodium stearate,magnesium stearate, sodium benzoate, sodium acetate, sodium chloride andthe like. Preservatives, stabilising agents, dyes and even flavouringagents may be provided in the pharmaceutical composition. Examples ofpreservatives include sodium benzoate, sorbic acid and esters ofp-hydroxybenzoic acid. Anti-oxidants and suspending agents may be alsoused.

A pharmaceutical composition comprising a compound of the presentinvention may be adapted for oral, rectal, vaginal, parenteral,intramuscular, intraperitoneal, intraarterial, intrathecal,intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal orsublingual routes of administration. For oral administration, particularuse may be of compressed tablets, pills, tablets, gellules, drops, andcapsules. For other forms of administration, a pharmaceuticalcomposition may comprise solutions or emulsions which may be injectedintavenousiy, intraarterially, intrathecally, subcutaneously,intradermally, intraperitoneally or intramuscularly and which areprepared from sterile or sterilisable solutions. A pharmaceuticalcomposition comprising a comprising of the present invention may also bein form of suppositories, pessaries, suspensions, emulsions, lotions,ointments, creams, gels, sprays, solutions or dusting powders. Apharmaceutical composition may be formulated in unit dosage form (ie inthe form of discrete portions containing a unit dose, or a multiple orsub-unit of a unit dose).

The compounds of the present invention may be provided as apharmaceutically acceptable salt including, for example suitable acidaddition or base salts thereof. A review of suitable pharmaceuticalsalts be Berge et al., J Pharm Sci 66:1-1.9 (1977). Salts are formed,for example with strong inorganic acids such as mineral acids (egsulfuric acid, phosphoric acid or hydrohalic acids), with strong organiccarboxylic acids such as alkanecarboxylic acids of to 4 carbon atomswhich are unsubstituted or substituted (eg by halogen) such as aceticacid, with saturated or unsaturated dicarboxylic acids (eg oxalic,malonic, succinic, fumaric, phthalic or tetraphthalic acid) withhydroxycarboxylic acids (eg ascorbic, glycolic, lactic, malic, tartaricor citric acid), with amino acids (eg aspartic or glutamic acid),benzoic acid, or with organic sulfonic acids (eg(C₁-C₄)-alkyl-aryl-sulfonic acids winch are unsubstituted substitutedby, for example, halogen) such as methane- or p-toluene sulfonic acid).

The compounds of the present invention may be provided in then variouscrystalline forms, polymorphic forms and (an)hydrous forms. In thisregard it is well known to those skilled in the art that chemicalcompounds may be isolated at any of such forms by slightly varying themethod of purification and or isolation from the solvents used in thesynthetic preparation of such compounds.

The present invention further provides a method of synthesising acompound according to the present invention, at a pharmaceuticallyacceptable salt, solvate or prodrug thereof.

With regard to the description of the synthetic methods described belowand in the referenced synthetic methods that are used to preparestarting materials, it will be understood by those skilled in the artthat all proposed reaction conditions, including choice of solvent,reaction atmosphere, reaction temperature duration of the experiment andworkup procedures can be readily selected. Moreover, it will beunderstood by those skilled in the art that the functionality present onvarious portions of the molecule must be compatible with the reagentsand reaction conditions utilised.

Necessary starting materials may be obtained by standard procedures oforganic chemistry. The preparation of such starting materials isdescribed in conjunction with the following representative processvariants and within the examples hereinafter. Alternatively, necessarystarting materials may be obtainable by analogous procedures to thoseillustrated which are within the ordinary skill of those skilled in theart. Further, it will be appreciated that during the synthesis of thecompounds, in the processes described below, or during the synthesis ofcertain starting materials, it may be desirable to protect certainsubstituent groups to prevent their undesired reaction. Those skilled inthe art will readily recognise when such protection is required, and howsuch protecting groups may be put in place, and later removed. Examplesof protecting groups are described in, for example, Protective Groups inOrganic Synthesis by Theodora Green (publisher John Wiley & Sons).Protecting groups may be removed by any convenient method well known tothose skilled in the art as appropriate for the removal of theprotecting group in question, such methods being chosen so as to effectremoval of the protecting group with the minimum disturbance of groupselsewhere in the molecule. Thus, if reactants include, for example,groups such as amino, carboxyl or hydroxyl, it may be desirable toprotect the group in some of the reactions mentioned herein.

The compounds of the present invention may be prepared by, for example,the general synthetic methodologies described in International PatentPublication No WO 2013/156780, which is herein incorporated byreference.

In a further of the present invention, a method of synthesising acompound of the present invention (or a pharmaceutically acceptablesalt, solvate or prodrug thereof) is provided wherein the methodcomprises:

-   -   a) reacting a compound of formula IV:

whereinz represents an optional bond such that the bond between N and theadjacent carbon atom can be a single or double bond; andR¹, R², R³, R⁸ and R⁹ are as defined in the first aspect;

-   -   with a compound of formula V:

wherein R⁴, R⁵, R⁶ and R⁷ are as defined in the first aspect; and ifnecessary

-   -   b) removing any protecting groups present, and/or forming a        pharmaceutically acceptable salt, solvate or prodrug thereof.

The coupling reaction between the compound of formula IV and formula Vmay take place in the presence of a suitable solvent or solvent mixture.Those skilled in the art will be able to readily select a suitablesolvent or solvent mixture for use in this reaction. Examples ofsuitable solvents include alcohols, acetonitrile, halogenated solvents,etc.

In addition, those skilled in the art will be able to select appropriatereaction conditions to use in the coupling reaction between the compoundof formula IV and formula V. However, typically, the reaction will becarried out in anhydrous conditions and in the presence of an inertatmosphere, such as argon or nitrogen. The reaction may also be carriedout an elevated temperature, such as, for example, within the range of80 to 180 C for a suitable time period of, for example, 20 minutes to 48hours. Suitably, the reaction is carried out under microwave heating,for example, at 80 to 180 C for 20 minutes to 1.5 hour.

The resultant compound can be isolated and purified using techniqueswell known to those skilled in the art.

The method of synthesising a compound of the present invention (or apharmaceutically acceptable salt, solvate or prodrug thereof) mayfurther comprise:

-   -   c) subjecting the compound of formula I to a salt exchange        (particularly in situations where the compound is formed as a        mixture of different salt forms).

The salt exchange may comprise immobilising the compound on a suitablesolid support or resin, and eluting the compound with an appropriateacid to yield salt of the compound of formula I (II or III).

An example of a particularly suitable method for synthesising a compoundof the present invention is shown as Scheme 1 below.

The invention is hereinafter described with reference to the following,non-limiting examples and accompanying figures.

EXAMPLES Example 1 Synthesis General

1_(H) and 13_(C) NMR spectra were recorded at 300 K on a Broker ADVANCEIII 500 spectrometer (1_(H) at 500 MHz and 13_(C) NMR at 125 MHz). 1_(H)and 13_(C) NMR spectra were referenced to 1_(H) signals of residualnon-deuterated solvents for tetramethylsilane) and 13 _(C) signals ofthe deurerated solvents respectively. High resolution mass spectra wererecorded on an AB SCIEX TripleTOF® 5600 mass spectrometer, andionisation of all samples was carried out using ESI. The purity ofcompounds was determined by analytical HPLC, and was greater than 95%.Analytic HPLC was carried out on a Shimadzu Prominence UFLC (UltraFastLiquid Chromatograph) system with a CBM-20A communications bus module, aDGU-20A_(5R) degassing unit, an LC-20AD liquid chromatograph pump, anSIL-20A_(BT) autosampler, an SPD-M20A photo diode array detector, aCTO-20A column oven and a Phenomenex Kinefex 5u C18 100A 250 mm×4.60 mmcolumn using. Method A (gradient 5 to 95% MeOH containing 0.1% FA over 7min, followed by 95% MeOH containing 0.1% FA over 13 min at a flow rateof 1 mL/min). Method B (gradient 5 to 95% MeCN containing 0.1% FA over 7min followed by 95% MeCN containing 0.1% FA over 13 min, at a flow rateof 1 mL/min).

1-(4-(6-((4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(I)

To a solution of acetylpiperazine (5.00 g, 39.0 mmol) and5-bromo-2-nitropyridine (5.00 g, 24.6 mmol) in DMSO (10 mL) was addedtriethylamine (10.2 mL, 73.9 mmol). The reaction mixture was heated at120° C. for 16 h, cooled down to room temperature and triturated withEtOAc. The formed solid was filtered and washed with EtOAc (10 mL) andH₂O (30 mL) to give the first portion of1-(4-(6-nitropyridin-3-yl)piperazin-1-yl)ethan-1-one as a yellow solid.The filtrate and washing were combined and extracted with DCM (3×100mL). The organic extracts were combined, dried over Na₂SO₄ andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH32 94:6) to give thesecond portion of 1-(4-(6-nitropyridin-3-yl)piperazin-1-yl)ethan-1-one.1_(H) NMR (CDCI₃) δ2.16 (s, 3H), 3.47 (t, 2H, J 5.5), 3.52 (t, 2H, J5.5), 3.71 (t. 2H, J 5.5). 3.83 (t, 2H, J 5.5). 7.23 (dd, 1H, J 9.5 &3.0), 8.14 (d. 1H, J 3.0), 8.20 (d, 1H. J 9.0). HRMS (ESI)251.1130([M+H]′):calcd. for C₁₁H₁₅N₄O₃ ⁺ ([M+H]⁺) 251.1139.

To a suspension of 1(4-((6-nitropyridin-3-yl)piperazin-1-yl)ethan-1-one(2.51 g, 10.0 mmol) in MeOH (200 mL) was added 10% Pd/C (107 mg, 0.100mmol, 1 mol %). The reaction mixture was bubbled with H₂ at roomtemperature for 5 h and filtered through a pad of Celite®. The solidswere washed with MeOH (50 mL). The filtrate and washing were combinedand concentrated under reduced pressure and in vacuo to give1-4-(6-aminopyridin-3-yl)piperazin-1-yl)ethan-1-one as a brownish solid(2.20 g, 100%), which was used in the next step without purification.HRMS (ESI); m/z 221.1390 [M+H]⁺; calcd. for C₁₁H₁₂N₄O⁺ 221.1397.

To a solution of 1-(4-(6-aminopyridin-3-yl)piperazin-1-yl)ethan-1-one(2.21 g. 10.0 mmol). N,N′-bis-Boc-S-methylisothiourea (3.50 g, 12.0mmol) and triethylamine(4.90 mL, 35.1 mmol) in DCM (100 mL) on an icebath was added HgCl₂ (5.45 g. 20.1 mmol). After stirring on an tee bathfor 0.5 h, the reaction mixture was warmed to room temperature, stirredfor 12 h and filtered through a pad of Celite®. The solids were washedwith DCM (50 mL). The filtrate and washing were combined andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM:MeOH=95.5 ramping to 90:10) to give1-acetyl-4-(6-(2,3-bis(tert-butoxycarbonyl)guanidino)pyridin-3-yl)piperazineas a light yellow solid (3.82 g, 82%). 1_(H) NMR (CDCl₃) δ 1.53 (s, 18H), 2.14 (s, 3H), 3.13 (t, 2H, J 5.5). 3.18 (t, 2H, J 5.5), 3.63 (t, 2H,J 5.5), 3.78 (t, 2H, J 5.5), 7.29 (dd, 1H, J 9.0 & 3.0), 7.87 (d, 1H, J7.5), 7.99 (d, 1H, J 2.5), 10.90 (br s, 1H), 11.58 (br s, 1H), HRMS(ESI): m/z 463.2668 [M+H]⁺; calcd. for C₂₂H₃₅N₆O₅ ⁺ [M+H]⁺ 463.2663.

To a solution of1-acetyl-4-6-(2,3-bis(tert-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine(724 mg, 1.56 mmol) in DCM (5 mL) was added TFA (5 mL). The reactionmixture was heated at reflux for 16 h and concentrated under reducedpressure. The residue was redissolved MeOH (50 mL), and a suspension ofexcess Ambersep® 900 resin (hydroxide form, pre-swelled with H₂O for 30min and MeOH for 30 min) in MeOH (50 mL) was added. The mixture wasstirred at room temperature overnight and filtered, and the solid waswashed with MeOH (50 mL). The filtrate and washing were combined andconcentrated under reduced pressure to give1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine as a beige solid(410 mg, 100%), which was directly used in the next step without furtherpurification. MS (ESI): m/z 263.2 [M−TFA+H]⁺.

To a mixture of crude 1-5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (1.08 g, 4.00 mmol) and(E)-(dimethylamino)-1-(2,4-dimethylthiazol-5-yl)prop-2-en-1-one (420 mg,2.00 mmol) in 2-methoxy ethanol (6 mL) was added NaOH (160 mg, 4.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=92:8) and recrystallised with DCM andhexane to give compound 1 as a yellow solid (100 mg, 12%). 1_(H) NMR (CDCl₃) δ2.09 (s, 3H), 2.64 (s, 3H), 2.65 (s, 3H), 3.20 (m, 4H), 3.58 (t,2H, J 5.0), 3.74 (t, 2H, J 5.0), 6.91 (d, 1H, J 5.5), 7.31 (dd, 1H, J9.0 & 3.0), 7.98 (d, 1H, J 2.5), 8.14 (s, 1H), 8.25 (d, 1H, J 9.0), 8.42(s, 1H, J 5.5). 13_(C) NMR (CDCl₃) δ18.3, 19.6, 21.5, 41.4, 46.3, 50.2,50.5, 109.4, 113.2, 127.4, 131.4, 137.5, 142.5, 146.9, 152.6, 158.7,159.0, 159.1, 167.1, 169.1. HRMS (ESI): m/z 410.1763 [M+H]⁺;calcd. forC20H24N7OS⁺ [M+H]⁺ 410.1758 Anal. RP-HPLC Method A: t_(R) 8.22 min,purity>99%, Method B: t_(R) 2.81 min. purity>99%.

4-(2,4-Dimethylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(2)

To a suspension of 1 (71.0 mg, 0.17 mmol) in methanol HCl (32%, 3 mL)was added and reflexed overnight. The reaction mixture was concentratedand purified by chromatography (silica gel, DCM ramping to DCM:MeOH:NH₄OH)=90:10:1) to give 2 as a yellow solid (49 mg, 77%) 1_(H) NMR(DMSO-d₆) δ2.63 (s, 3H), 2.65 (s, 3H), 3.11 (t, 4H, J 5.5), 3.26 (t, 4H,J 4.5), 7.11 (d, 1H, J 5.0). 7.49(dd, 1H, J 9.0 & 3.0), 8.05 (d, 1H, J3.0), 8.10 (d, 1H, J 9.0), 8.53 (d, 1H, J 5.5), 9.70 (br, 1H). HRMS(ESI): m/z 368.1653 [M+H]⁺; calcd. for C18H22N7S⁺ [M+H]⁺ 368.1652 Anal.RP-HPLC Method A: t_(R) 8.00 min, purity>98%, Method B: t_(R) 2.88 min,purity>96%.

The following compounds were synthesised by an analogous route.

4-(2,4-dimethylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(3)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2,4)-dimethylthiazol-5-yl)prop-2-en-1-one (210mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=92:8) and recrystallised with DCM andhexane to give 2 as a yellow solid (119 mg, 31%). m.p. 183-184° C. 1_(H)NMR (CDCl₃) δ2.36 (s, 3H), 2.60 (t, 4H, J 5.0), 2.70 (s, 3H), 2.71 (s,3H), 3.19 (t, 4H, J 5.0), 6.95 (d, 1H, J 5.0), 7.37 (dd, 1H, J 9.0 &3.0), 8.05 (d, 1H, J 2.5), 8.23 (br, 1H), 8.27 (d, 1H. J 9.0), 8.48 (d,1H, J 5.0). HRMS (ESI): m/z 382.1788 [M+H]⁺; calcd. for C₁₉H₂₄N₇S⁺[M+H]⁺ 382.1808. Anal. RP-HPLC Method A: t_(R) 8.54 min, purity>99%,Method B: t_(R) 3.23 min, purity>99%.

4-(2,4-Dimethylthiazol-5-yl)-2-((5-(piperazin-1-yl) pyridin-2-yl) amino)pyrimidine-5-carbonitrile (4)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and(E)-3-(dimethylamino)-2-(2,4-dimethylthiazole-5-carbonyl)acrylonitrile(235 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=95:5) and recrystallised with DCM andhexane to give 4 as a yellow solid (90 mg, 25%). m.p. 110-113°0 C. 1_(H)NMR (DMSO-d₆) δ2.91 (s, 4H, thiazole-CH₃ & piperazine-NH), 3.11 (s, 3H),3.27 (t, 4H, J 4.5), 3.48 (t, 4H, J 4.0), 7.84 (dd, 1H, J 9.0 & 3.0),8.31 (d, 1H, J 9.0), 8.48 (d, 1H, J 2.0), 9.33 (s, 1H), 11.13 (s, 1H).HRMS (ESI): m/z 393.1597 [M+H]⁺; calcd. for C₁₉H₂₁N₈S⁺ [M+H]⁺ 393.1004.Anal. RP-HPLC Method A: t_(R) 9.18 min, purity>95%; Method B: t_(R) 7.68min, purity>96%.

4-(2,4-Dimethylthiazol-5-yl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-5-carbonitrile(5)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-2-(2,4-dimethylthiazole-5-carbonyl)acrylonitrile(235 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=90:10) and recrystallised with MeOH to give5 as a brown solid (114 mg, 28%). m.p 112-114° C. 1H NMR (CDCl₃) δ2.37(s, 3H), 2.60 (t, 4H, J 5.0), 2.63 (s, 3H), 2.76 (s, 3H), 3.21 (t, 4H, J5.0). 7.33 (dd. 1H, J 9.0 & 3.0), 8.13 (s. 1H, 8.20 (d, 1H, J 9.0), 8.76(s, 1H), 8.76 (s, 1H). HRMS (ESI): m/z 407.1772 [M+H]⁺; calcd. forC₁₉H₂₁N₈S⁺ 407.1761. Anal. RP-HPLC Method A: t_(R) 9.58 min, purity100%; Method B: δ8.18 min, purity 100%.

2-((5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)amino)-4-(2,4-dimethylthiazol-5-yl)pyrimidine-5-carbonitrile (6)

To a mixture of crude1-(5-(4-acctylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524 mg, 2.00 mmol) and(E)-3-(dimethylamino)-2-(2,4-dimethylthiazole-5-carbonyl)acrylonitrile(235 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=90:10) and recrystallised with DCM andhexane to give 6 as a yellow solid (150 mg, 34%). m.p. 99-101° C. 1_(H)NMR (DMSO-d₆) δ1.79 (s, 3H), 2.25 (s, 3H), 2.45 (s, 3H), 2.85 (d, 2H, J4.0), 2.92 (s, 2H), 3.33 (d, 4H, J 4.0), 7.22 (dd, 1H, J 9.0 & 3.0),7.67 (d, 1H, J 9.0), 7.85 (d, 1H, J 2.5), 8.68 (s, 1H), 10.47 (s, 1H).HRMS (ESI): m/z 435.1700 [M+H]⁺;calcd. for C₂₂H₂₉N₈S⁺ [M+H]⁺ 435.1710.Anal. RP-HPLC Method A: t_(R) 10.92 min, purity>97%: Method B: t_(R)8.69 min, purity>96%.

4-(2-Ethyl-4-methylthiazol-5-yl)-N-(5-piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(7)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and(E)dimethylamino)-1-(2-ethyl-4-methylthiazol-5-yl)prop-2-en-1-one(224mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg. 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM tamping to DCM:MeOH=91.9) and recrystallised with MeOH to give7 as a yellow solid (35 mg, 9%). 1_(H) NMR (DMSO-d₆) δ1.32 (t, 3H, J7.5), 2.65 (s, 3H), 2.98 (q, 2H, J 7.5), 3.26 (t, 4H, J 2.5), 3.34 (apps, 4H), 7.13 (d, 1H, J 5.0), 7.52 (dd, 1H, J 9.5 & 3.5), 8.07 (d, 1H, J3.0), 8.11 (d, 1H, J 9.0), 8.53 (d, 1H, J 5.5), 8.66 (s, M), 9.65 (s,1H), HRMS (ESI): m/z 382.1810 calcd. for C₁₉H₂₄N₇S⁺ [M+H]⁺ 382.1808.Anal. RP-HPLC Method A: t_(R) 12.55 min, purity>99%; Method B: t_(R)3.71 min, purity>98%.

4-(2-Ethyl-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(8)

To a mixture of crude1-5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-ethyl-4-methylthiazol-5-yl)prop-2-en-1-one(224mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=91:9) and recrystallised with MeOH to give8 as a yellow solid (50 mg, 13%). 1_(H) NMR (CDCl₃) δ1.41 (t, 3H, J7.5), 2.34 (s, 3H), 2.58 (t, 4H, J 5.0), 2.69 (s, 3H), 3.00 (q, 2H, J7.5), 3.18 (t, 4H, J 5.0), 6.93 (d, 1H., J 5.0), 7.35 (dd, 1H, J 9.0 &3.0), 8.12 (d, 1H, J 3.0), ), 8.28 (d, 1H, J 9.0), 8.52 (d, 1H, J 5.5),8.97 (s, 1H), HRMS (ESI): m/z 396.1980 [M+H]⁺; calcd. torC₁₉H₂₄N₇S⁺[M+H]⁺ 396.1965. Anal. RP-HPLC Method A: t_(R) 12.58 min.purity>99%; Method B: t_(R) 3.86 min, purity>96%.

4-(2-Ethyl-4-methylthiazol-5-yl)-N-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(9)

To a mixture of crude 1-5-(4-ethylpiperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (497 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-ethyl-4-methylthiazol-5-yl)prop-2-en-1-one(224 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=95.5) and recrystallised with MeOH to give9 is a yellow solid (51 mg, 13%) 1_(H) NMR (CDCl₃) δ1.13 (t, 3H, J 7.5)1.42 (t, 3H, J 7.5), 2.49 (q, 2H, J 7.0), 2.63 (t, 4H, J 5.0), 2.70 (s,3H), 3.02 (q, 2H, J 8.0₃), (t, 4H, J 5.0), 6.95 (d, 1H, J 5.0), 7.36(dd, 1H, J 9.0 & 3.0), 8.07 (d, 1H. J 3.0),), 8.28 (d, 1H, J 9.5), 8.40(s, 1H), 8.49 (d, 1H, J 5.5), HRMS (ESI): m/z 410.2129 [M+H]⁺; calcd.for C₂₁H₂₈N₇ ⁺ [M+H]⁺410.2121. Anal. RP-HPLC Method A: t_(R) 12.61 rain,purity>99%; Method B: t_(R) 3.82 rain, purity>94%.

1-(4-(6-((4-(2-Ethyl-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(10)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524 mg, 2.00 mmol)and(E)-3-(dimethylamino)-1-(2-ethyl-4-methylthiazol-5-yl)prop-2-en-1-one(224 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silica gelDCM ramping to DCM: MeOH=95:5) and recrystallised with MeOH to give 10as a yellow solid (175 mg, 41%) 1H NMR (CDCl₃) δ1.43 (t, 3H, J 7.5),2.15 (s, 3H), 2.71 (d, 3H, J 2.5), 3.03 (q, 2H, J 8.0), 3.12 (t, 2H, J5.0). 3.15 (t, 2H, J 5.0), 3.65 (s, 6H), 3.80 (t, 2H, J 5.0), 3.78 (t,2H, J 5.0), 6.98 (d, J 5.5, 1H), 7.37 (dd, 1H, J 9.0 & 3.0), 8.03 (d,1H, J 3.0), 8.05 (s, 1H), 8.32 (d, 1H, J 9.0), 8.48 (d, J 5.5, 1H), HRMS(ESI): m/z 424.1932 [M+H]⁺; calcd. for C₂₁H₂₆N₇OS⁺ [M+H]⁺ 424.1914.Method A: 14.52 min, purity 100%; Method B: t_(R) 10.33 min, purity100%.

1-(4-(6-((5-Chloro-4-(2-ethyl-4-methylthiazol)-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (11)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524mg, 2.00 mmol) and(E)-2-chloro-3-(dimethylamino)-1-2-ethyl-4-methylthiazol-5-yl)prop-2-en-2-one(259 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=96:4) and recrystallised with MeOH to give11 as yellow solid (30 mg, 7%). 1_(H) NMR (CDCl₃) δ1.44 (t, 3H, J 7.5),2.15 (s, 3H), 2.54 (s, 3H), 3.05 (q, 2H, J 7.5), 3.10 (t, 2H, J 5.0),3.13 (t, 2H, J 5.0), 3.64 (t, 2H, J 4.5), 3.79 (t, 2H, J 5.0) 7.32 (dd,1H, J 9.0 & 3.0), 8.03 (d, 1H, J 2.5), 8.22 (d, 1H, J 9.0), 8.31 (d, J5.5, 1H), 8.49 (s, 1H, NH), HRMS (ESI): m/z 458.1525 [M+H]⁺; calcd. forC₂₁H₂₅ClN₇OS⁺ [M+H]⁺ 458.1524. Anal. RP-PLC Method A: t_(R) 11.26 min.purity>99%. Method B: t_(R) 8.76 min, purity>98%.

4-(2-Ethyl-4-methylthiazol-5-yl)-N-(5-morpholinopyridin-2-yl)pyrimidin-2-amine(12)

To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidinetrifluoroacetate (442 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-ethyl-4-methylthiazol-5-yl)prop-2-en-1-one(224mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=94:6) and recrystallised with MeOH to give12 as a yellow solid (61 mg, 16%). 1_(H) NMR (CDCl₃) δ1.43 (t, 3H, J7.5), 2.71 (d, 3H, J 2.5), 3.03 (q, 2H, J 7.5), 3.14 (t, 4H, J 5.0),3.89 (t, 4H, J 5.0), 6.97 (d, J 5.0, 1H), 7.35 (dd, 1H, J 9.9 & 3.0),7.99 (s, 1H), 8.02 (d, 1H, J 2.5), 8.30 (d, 1H, J 9.0), 8.47 (d, J 5.5,1H) HRMS (ESI) m/z 383.1656 [M+H]⁺; calcd. for C₁₉H₂₃OS⁺ [M+H]⁺383.1649. Anal. RP-HPLC Method A: t_(R) 14.71 min, purity>98%; Method B:t_(R) 10.48 min, purity>97%.

4-(2-Isopropyl-4-methylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(13)

To a suspension ofN-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)-4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2-amine(150 mg, 0.34 mmol) in methanol HCl (32%, 3 mL) was added and re flexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to DCM: MeOH: NH₄OH)=90:10:1) togive 13 as a yellow solid (108 mg, 80%), R_(P) (DCM:MeOH=9.1+10 drops of32% aqueous ammonia) 0.10. 1_(H) NMR (CDCl₃) 67 1.43 (d, 6H, J 7.0),1.65 (br, 1H), 2.71 (s, 3H), 3.07 (t, 4H, J 2.0), 3.11 (t, 4H, J 3.0),3.30 (m, 1H), 6.96 (d, 1H, J 5.5), 7.36 (dd, 1H, J 9.0 & 3.0), 7.97 (s,1H), 8.02 (d, 1H, J 3.0), 8.28 (d, 1H, J 9.0), 8.46 (d, 1H, J 5.5). HRMS(ESI): m/s 396.1961 calcd. for C₂₀H₂₆N₇S⁺ [M+H]⁺ 396.1965. Anal. RP-HPLCMethod A: t_(E) 9.08 min, purity>98%; Method B: 7.44 min, purity 100%.

4-(2-Isopropyl-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(14)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-isopropyl-4-methylthiazol-5-yl)prop-2-en-1-one(238 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was healed at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM: MeOH=90:10) and recrystallised with MeOH togive 14 as a yellow solid (200 mg, 48.9). 1_(H) NMR (DMSO-₆) δ1.34 (d,6H, J 7), 2.21 (s, 1H), 2.45 (t, 4H, J 5), 2.63 (s, 3H), 3.11 (t, 4H, J4.5), 3.25 (m, 1H), 7.09 (d, 1H, J 5.5), 7.44 (dd, 1H, J 9.5 & 3.0),8.01 (d, 1H, J 3.0), 8.07 (d, 1H, J 9.5), 8.52 (d, 1H, J 5.5), 9.66 (s,1H), HRMS (ESI): m/z 410.121 [M+H]⁺; calcd. for C₂₁H₂₈N₇S⁺ [M+H]⁺410.2121. Anal. RP-HPLC Method A: t_(R) 9.14 min, purity>97%: Method B:t_(R) 7.53 min. purity 100%.

N-(5-(4-Ethylpiperzin-1-yl)pyridin-2-yl)-4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2-amine(15)

To a mixture of crude 1-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (496.6 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-isopropyl-4-methylthiazol-5-yl)prop-2-en-1-one(238 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol) The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underseduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=93:7) to give 15 as a light yellow solid(178 mg, 42%). 1_(H) NMR (CDCl₃) δ1.14 (t, 3H, J 7.0), 1.43 (d, 6H, J7.0), 2.50 (q, 3H, J 7.0), 2.64 (t, 4H, J 5.0), 2.71 (s, 3H), 3.20 (t,4H, J 5.0). 3.30 (m, 1H), 6.96 (d, 1H, J 5.5), 7.36 (dd, 1H, J 9.5 &3.0), 8.05 (d, 1H, J 2.5), 8.17 (s, 1H), 8.33 (d, 1H, J 9.5), 8.47 (d,1H, J 5.5). HRMS (ESI): m/z 424.2298 [M+H]⁺; calcd. for C₂₂H₂₀N₇S⁺[M+H]⁺ 424.2278. Anal. RP-HPLC Method A: t_(R) 9.18 min, purity>99%;Method B: t_(R) 7.15 min, purity>98%.

1-(4-(6-((4-(2-Isopropyl-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(16)

To a mixture of crude 1-5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (524 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-isopropyl-4-methylthiazol-5-yl)prop-2-en-1-one(238 mg, 1.09 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=93:7) to give 16 as a yellow solid (360 mg,42%). 1_(H) NMR (DMSO-d6) δ1.41(d, 6H, J 7), 2.13 (s, 1H), 2.9 (s, 3H),3.11 (app m, 4H), 3.28 (m. 1H), 3.62 (t, 2H, J 5.0), 3.78 (t, 2H, J5.0), 6.96 (d, 1H, J 5.5), 7.35 (dd, 1H, J 9.5 & 3.0), 8.14 (d, 1H, J2.5), 8.33 (d, 1H, J 9.5), 8.55 (d, 1H, J 5.0), 9.24 (s, 1H), HRMS(ESI): m/z 438.2088 calcd. for C₂₂H₂₈N₇OS⁺ 438.2071, Anal. RP-HPLCMethod A: t_(R) 10.50 min, purity>98%; Method B: t_(R) 8.45 min.purity>98%.

4-(2-Isopropyl-4-methylthiazol-5-yl)-N-(5-morpholinopyridin-2-yl)pyrimidin-2-amine(17)

To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidinetrifluoroacetate (331.7 mg, 1.50 mmol) and(E)-(dimethylamino)-1-(2-isopropyl-4-methylthiazol-5-yl)prop-2-en-1-one(238 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (60.0 mg,1.50 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=97:3) to give 17 as a white solid (238 mg,60%). 1_(H) NMR (CDCl₃) δ1.43 (d, 6H, J 7.0), 2.71 (s, 3H), 3.14 (t, 4H,J 5.0), 3.32 (m, 1H), 3.89 (t, 4H J 5.0), 6.97 (d, 1H, J 5.0), 7.35 (dd,1H, J 9.0 & 3.0), 8.09 (d, 1H, J 3.0), 8.10 (s, 1H), 8.31 (d, 1H, J 9),8.46 (d, 1H, J 5.0), HRMS (ESI); m/z 397.1797 [M+H]⁺; calcd. forC₂₀H₂₅N₆OS⁺) [M+H]⁺ 397.1805 Anal. RP-HPLC Method A: t_(R) 10.97 min,purity>99%; Method B: t_(R) 8.68 min, purity 100%.

N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2-amine(18)

To a mixture of 1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperazine (341mg, 1.20 mmol) and 4-(2-isopropyl-4-methylthiazol-5-yl)pyrimidin-2-amine(234.3 mg, 1.00 mmol) in dioxane (3 mL) were added Pd₂dba₃ (45.8 mg,0.05 mmol), xantphose (57.9 mg, 0.1 mmol) and t-BuONa (144.2 mg,1.50mmol). The reaction mixture was heated at 150° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel. DCM ramping to DCM:MeOH=98:2) to give 18 as a white solid (210 mg,48%). _(H) NMR (DMSO-d₆) δ0.97 (t, 3H, J 7.5), 1.36 (d, 6H, J 7.0), 2.28(q, 2H,, J 7.5), 2.36 (s br, 8H), 2.67 (s, 3H), 3.24-3.30(m, 1H), 3.42(s. 1H), 7.17 (d, 1H, J 5.5), 7.70 (dd, 1H, J 8.5 & 2.0), 8.20 (d, 1H, J2.0), 8.22 (d, 1H, J 8.5), 8.58 (d, 2H, J 5.5), 9.92 (s, 1H), HRMS(ESI): m/z 438.2435 [M+H]⁺; calcd. for C₂₃H₃₂N₇S⁺ [M+H]⁺438.2434 Anal.RP-HPL.C Method A: t_(R) 9.43 min, purity>97%, Method B: t_(R) 8.66 min,purity>98%,

4-(2-Methoxy-1-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(19)

To a mixture of crude1-5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(374 mg, 1.60 mmol) and(E)-3-(dimethylamino)-1-(2-methoxy-4-methylthiazol-5-yl)prop-2-en-1-one(183 mg, 0.80 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (64.0 mg,1.60 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=94:6) to give 19 as a yellow solid (52 mg,13%). m.p. 190-192° C. 1_(H) NMR (CDCl₃) 2.37 (s, 3H), 2.58 (s, 3H),2.60 (t, 4H, J 5.0), 3.19 (t, 4H, J 5.0), 3.37 (s, 3H), 6.73 (d, 1H, J5.0), 7.34 (dd, 1H, J 9.0 & 3.0), 7.97 (s, 1H), 8.01 (d, 1H, J 3.0),8.21 (d, 1H, J 9.0), 9.40 (d, 1H, J 5.0). HRMS (ESI): m/z 398.1779[M+H]⁺: calcd. for C₁₉H₂₄N₇OS⁺ [M+H]⁺ 398.1758. Anal. RP-HPLC Method A:t_(R) 8.36 min, purity>97%; Method B: t_(R) 3.59 min, purity>99%.

4-(4-Methyl-2-(methylthio)thiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(20)

To a suspension of1-(4-(6-((4-(4-Methyl-2-(methylthio)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one1100 mg, 0.23 mmol) in methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to DCM:MeOH: NH₄OH)=90:10:1) togive 20 as a yellow solid (77 mg, 85%). 1_(H) NMR (DMSO-d₆) δ2.64 (s,3H), 2.74 (s, 3H), 3.23 (t, 2H, J 5.5), 3.36 (app s, 4H), 7.12 (d, 1H, J5.5), 7.54 (dd, 1H, J 9.0 & 3.0), 8.06 (d, 1H, J 3.0), 8.08 (d, 1H, J9.0), 8.53 (s, 1H, J 5.5), 8.82 (s, 1H), 9.69 (s, 1H). HRMS (ESI): m/z400.1390 [M+H]⁺; calcd. for C₁₈H₂₂N₇S₂ ⁺ [M+H]⁺ 400.1373 Anal. RP-HPLCMethod A: t_(R) 8.85 min, purity>98%, Method B: 7.44 min, purity>99%.

4-(4-Methyl-2-(methylthio)thiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(21)

To a mixture of crude 1-(5-(4-methylpiperazin-1-yl)pyridine -2-yl)guanidine trifluoroacetate (468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(4-methyl-2-(methylthio)thiazol-5-yl)prop-2-en-1-one(242 mg. 1.00 mmol) in acetonitrile (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure The residue was purified by chromatography (silica gel,DCM ramping to DCM:MeOH=94:6) to give 21 as a yellow solid 200 mg, 48%;.m.p. 206-207° C. 1_(H) NMR (CDCl₃) 2.37 (s, 3H), 2.61 (t, 4H, J 5.0),2.69 (s, 3H), 2.73 (s, 3H), 3.19 (t, 4H, J 5.0), 6.93 (d, 1H, J 5.0),7.36 (dd. 1H, J 9.0 & 3.0), 8.05 (d, 1H, J 3.0), 8.20 (s, 1H), 8.24 (d,1H, J 9.0), 8.46 (d, 1H, J 5.0) HRMS (ESI): m/z 414.1552 [M+H]⁺; calcd.for C₁₉H₂₄N₇S⁺ [M+H]⁺ 414.1529. Anal. RP-HPLC Method A: t_(R) 9.36 min,purity>99%. Method B: t_(R) 7.83 min, purity>99%.

1-(4-(6-((4-(4-Methyl-2-methythio)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(22)

To a mixture of crude to a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluroacetate (524mg, 2.00 mmol; 468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(4-methyl-2-(methylthio)thiazol-5-yl)prop-2-en-1-one(242 mg, 1.00 mmol) in acetonitrile(3 mL) was added NaOH (80.0 mg. 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h. cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=95:5) to give 22 as a yellow solid (141 mg,32%). 1_(H) NMR (CDCl3) δ2.15 (s, 3H), 2.69 (s, 3H), 2.73 (s, 3H), 3.13(app m, 4H), 3.64 (t, 2H, J 5.0). 3.80 (t, 2H, J 5.0), 6.95 (d, 1H, J5.5), 7.3 7(dd, 1H, J 9.0 & 3.0), 8.08 (d, 1H, J 3.0), 8.29 (d, 1H, J9.0). 8.49 (s, 1H, J 5.0), 8.53 (s, 1H). HRMS (ESI): m/z 442.1478[M+H]⁺; calcd. for C₂₀H₂₄N₇OS₂ ⁺ [M+H]⁺ 442.1486 Anal. RP-HPLC Method A:t_(R) 8.23 min, purity>97%. Method B: t_(R) 2.81min, purity 100%.

4-(2-(Isopropylthio)-4-methylthiazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(23)

To a suspension of1-(4-(6-((4-(2-(isopropylthio)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(100 mg, 0.21 mmol) in methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to DCM:MeOH: NH3OH)=90:10:1) togive 23 as a yellow solid (82 mg, 90%). 1_(H) NMR(CDCl₃) 1.47 (s, 3H),1.48 (s, 3H), 2.7 (s, 3H), 3.06 (t, 4H, J 4.5), 3.13 (t, 4H, J 5.0),3.89 (m, 1H), 6.94 (d, 1H, J 5.0), 7.36 (dd, 1H, J 9.0 & 3.0), 8.03 (d,1H, J 3.0), 8.04 (s, 1H), 8.25 (d, 1H, J 9.0), 8.46 (d, 1H, J 5.0).HRMS(ESI): m/z 428.1696 [M+H]⁺;calcd. for C₂₀H₂₆N₇S₂ ⁺ [M+H]⁺ 428.1686.Anal. RP-HPLC Method A: t_(R) 9.86 min, purity>93%: Method B: t_(R) 7.96min, purity >96%.

4-(2-(Isopropylthio)-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine(24)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.0 mmol) and(E)-3-(dimetylamino)-1-(2-(isopropylthiol-4-methylthiazol-5-yl)prop-2-en-1-one(270 mg, 1.00 mmol) in acetonitrile (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=90:10) to give 24 as a yellow solid (97 mg,22%), m.p. 198-200° C. 1_(H) NMR (CDCl₃) 1.46 (s, 3H), 1.47 (s, 3H),2.37 (s, 3H), 2.61 (t, 4H, J 5.0), 2.69 (s, 3H), 3.19 (t, 4H, J 5.0),3.88(m, 1H), 6.93 (d, 1H, J 5.0), 7.36 (dd, 1H, J 9.0 & 3.0), 8.08 (s,1H), 8.25 (d, 1H, J 9.0), 8.49 (d, 1H, J 5.0), 8.62 (s, 1H). HRMS (ESI):m/z 442.1865 [M+H]⁺; calcd. for [M+H]⁺ 442.1842. Ana;. RP-HPLC Method A:t_(R) 10.34 min, purity>96%: Method B: 8.36 min, purity>98%.

1-(4-(6-((4-(2-(Isopropylthio)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(25)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(2-(isopropylthio)-4-methylthiazol-5-yl)prop-2-en-1-one(270 mg, 1.00 mmol) in acetonitrile (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=94:6) to give 25 as a yellow solid (193 mg,41%). 1_(H) NMR (CDCl₃) δ1.47 (s, 3H), 1.48 (s, 3H), 2.15 (s, 3H), 2.70(s, 3H), 3.13 (app m, 4H), 3.65 (t, 2H, J 5.0), 3.80 (t, 2H, J 5.0),3.89 (m, 1H), 6.95 (d, 1H, J 5,5), 7.37 (dd, 1H, J 9.0 & 3.0), 8.05 (d,1H, J 3.0), 8.29 (app br d, 2H), 8.48 (d, 1H, J 5.0). HRMS (ESI); m/z470.1787 [M+H]⁺; calcd. for C₂₂H₂₈N₇OS₂ ⁺ [M+H]⁺ 470.1791 Anal. RP-HPLCMethod A: t_(R) 8.23 min, purity>93%, Method B: t_(R)2.81 min,purity>95%

N,4-Dimethyl-5-(2-((5-piperazin-1-yl)pyridine-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(26)

To a solution of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guamdinetrifluoroacetate (264 mg, 1.20 mmol) in 2-methoxyethanol (4 mL) wereadded(E)-3-dimethylamino)-1-4-methyl-2-(methylamino)th)thiazol-5-yl)prop-2-en-1-one(225 mg, 1.00 mmol) and NaOH (82.0 mg, 2.40 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, chloroformramping to chloroform:MeOH=91:9 with consecutive addition of 32% aqueousammonia, up to 10%). The solid was washed with DCM and MeOH, thenfiltered to give 26 as a pale yellow solid (94.0 mg, 24%). 1_(H) NMR(DMSO-d₆) δ2.47 (s, 3H), 2.83 (t, 4H, J 5.0), 2.87 (d, 3H, J 4.5). 3.01(t, 4H, J, 5.0), 6.91 (d, 1H, J 5.5), 7.38 (dd, 1H, J 9.0 & 3.0), 7.97(d, 1H, J 3.0), 8.04-8.07 (m. 2H), 8.33 (d, 1H, J 4.0), 9.25 (s, 1H). MS(ESI): m/z 383.1674 [M+H]⁺; calcd. for C₁₈H₂₃N₈S⁺ [M+H]⁺ 383.1761. Anal.RP-HPLC Method A: t_(R) 8.37 min, purity>99%; Method B; t_(R) 7.10 mm,purity 99%.

4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile(27)

To a solution of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (264 mg, 1.20 mmol) in 2-methoxyethanol (4 mL) wereadded tert-butyl(E)-(5-(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(350 mg, 1.00 mmol) and NaOH (82.0mg, 2.40 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, chloroformramping to chloroform: MeOH=91:9 with consecutive addition of 32%aqueous ammonia, up to 3 mL). The solid was washed with DCM and MeOH,and then filtered to give 27 as a pale yellow solid (131 mg, 32%). 1_(H)NMR (DMSO-d₆) δ 2.41 (s, 3H), 2.88-2.89 (m, 7H), 3.07 (t, 4H,. J 5.5),7.41 (dd, 1H, J 9.0 & 3.0), 7.88 (d, 1H, J 9.0), 8.03 (d, 1H, J 3.0),8.26 (q, 1H, J 4.5), 8.75 (s, 1H), 10.30 (s, 1H). MS (ESI): m/z 408.1660[M+H]⁺; calcd. for C₁₉H₂₂N₉S⁺ [M+H]⁺ 408.1713.

5-(5-Fluoro-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(28)

To a suspension of1(4-(6-((5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(200 mg, 0.45 mmol) m methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to EtOAc MeOH: NH₄OH)=90:10:1)to give 28 as a yellow-solid (140 mg. 77%). 1_(H) NMR (DMSO-d₆) 2.47 (d,3H, J 2.0), 2.83 (t, 4H, J 4.5), 2.87 (d, 3H, J 4.5). 3.00 (t, 4H, J5.0), 7.37 (dd, 1H, J 9.0 & 2.5), 7.94 (d, 1H, J 9.0), 7.96 (d, 1H, J3.0), 8.11 (app d, 1H, J 4.5). 8.41 (d, 1H, J 3.0), 9.48 (s, 1H). H MS(ESI): m/z 401.1678 [M+H]⁺; calcd. for C₁₈ H₂₂FN₈S⁺ [M+H]⁺ 101.1667.Anal. RP-HPLC Method A: t_(R) 8.14 min, purity>95%; Method B: t_(R) 2.80min, purity 100%.

N,4-Dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridine-2-yl)amino)pyridine-4-yl)thiazol-2-amine(29)

To a solution of crude1(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(200 mg, 0.854 mmol) in 2-methoxyethanol (4.0 mL) was added(E)-3-(dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-yl)prop-2-en-1-oneand NaOH (58.1 mg, 171 mmol). The reaction mixture was heated at 160 for30 min, cooled down to room temperature and concentrated under reducedpressure. The residue was purified by chromatography (silica gel, DCMramping to DCM:MeOH=91:9) and washed with DCM and MeOH to give 29 as apale yellow solid (91.0 mg, 27 %,). 1_(H) NMR (DMSO-d₆) δ2.22 (s, 3H,2.45-2.47 (m, 7H), 2.87 (d, 3H, J 4.5), 3.11 (t, 4H, J 5.0), 6.91 (d,1H, J 5.5), 7.40 (dd, 1H, J 9.0 & 3 0), 7.99 (d, 1H, J 3.0), 8.06-8.08(m, 2H), 8.33 (d, 1H, J 5.5), 9.24 (s, 1H). MS (ESI): m/z 397.1958calcd. for C₂₀H₂₅N₇S⁺ [M+H]⁺ 397.1917.Anal. RP-HPLC Method A: t_(R) 8.27mm. purity>90%; Method B: t_(R) 7.09 mm, purity>94%.

4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile(30)

To a solution of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) in 2-methoxyethanol (4 mL) were added tert-butyl(E)-(5-(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(350 mg, 1.00 mmol) and NaOH (136mg, 4.00 mmol). The reaction mixturewas healed at 180° C. for 60 min, cooled down to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel. DCM lamping to DCM:MeOH=91:9) and washedwith DCM and MeOH, to give 30 as a pale yellow solid (363 mg, 43%).1_(H) NMR (DMSO-d6) δ2.43 (s, 3H), 2.74 (s, 3H), 2.89 (d, 4H, J5.0),3.17 (d, 4H, J 5.0),7.50 (dd, 1H, J 9.0 & 3.0), 7.93 (d, 1H, J9.0), 8.11 (d, 1H, J 3.0), 8.28 (d, 1H, J 4.5), 8.77 (s, 1H), 10.39 (s,1H). MS (ESI): m/z 422.1808 [M+H]⁺; calcd. for C₂₀H₂₄N₉S⁺ [M+H]⁺422.1870. Anal. RP-HPLC Method A: t_(R) 8.72 min. purity>99%; Method B:t_(R) 7.36 min, purity>99%.

5-(5-Fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(31)

To a solution of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (80.0 mg. 2.00mmol) The reaction mixturewas heated at 180° C. for 60 min. cooled down to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH:NH₄OH=92:8:1) andwashed with DCM and MeOH, to give 31 as a reddish brown solid (124 mg,30%). 1_(H) NMR (DMSO-d₆) δ2.22 (s, 3H), 2.45 (t, 4H, J 4.5), 2.47 (appd, 3H, J 2), 2.87 (d, 3H, J 5), 3.10 (t, 4H, J 5), 7.40 (dd, 1H, J 9.0 &3.0), 7.95 (d, 1H, J 9.0), 7.97 (d, 1H, J 3.0), 8.11 (q, 1H, J 4.5),8.42 (d, 1H, J 3.5), 9.53 (s, 1H.) HRMS (ESI): m/z 415.1846 [M+H]⁺;calcd. for C₁₉H₂₄FN₈S⁺ [M+H]⁺ 415.1823. Anal. RP-HPLC Method A: t_(R)8.09 min. purity>95%: Method B: t_(R) 2.83 min, purity 99%.

5-(2-((5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(32)

To a solution of crude1-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(496.0 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-2-fiuoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 60 min, cooled down to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=90:10) to give 32 asa yellow solid (146 mg, 34%), 1_(H) NMR (DMSO-d₆) δ1.03 (t, 3H, J 7.0),2.36 (q. 3H, J 7.0), 2.48 (app d, 3H, J 2.0), 2.50(br, 4H), 2.87 (d, 3H,J 5.0), 3.10 (t, 4H, J 5.0), 7.39 dd, 1H, J 9.0 & 3.0), 7.96 (d. 1H, J9.0), 7.99 (d, 1H, J 3.0), 8.13 (q, 1H, J 4.5), 8.43 (d, 1H, J 3.5),9.55 (s, 1H) HRMS (ESI): m/z 429.1982 [M+H]⁺; calcd. for [M+H]⁺429.1980. Anal. RP-HPLC Method A: t_(R) 8.30 min, purity 100%; Method B:t_(R) 2.80 min, purity 100%.

1-(4-(6-((4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(33)

To a solution of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifiuoroacetate(525mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(225 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel. DCM ramping toDCM:MeOH=90:10+0.5 ml of 32% ammonia) to give 33 as a yellow solid (100mg, 24%). 1_(H) NMR (CDCl₃) δ 2.15 (s, 3H), 2.56 (s, 3H), 3.05 (s, 3H),3.10 (t, 2H, J 4.5). 3.14 (t, 2H, J 4.5), 3.64 (t, 2H, J 4.5), 3.79 (t,2H, J 4.5), 5.73 (s, 1H), 6.88 (d, 1H, J 5.5), 735 (dd, 1H, J 9.0 &2.5). 7.89 (s, 1H), 8.01 (d, 1H, J 2.0), 8.31 (d, 1H, J 9.0), 8.35 (d,1H, J 5.0). HRMS (ESI): m/z 425.1878 [M+H]⁺; calcd. for C₂₆H₂₅N₈OS⁺[M+H]⁺ 425.1867. Anal. RP-HPLC Method A: t_(R)9.92 min, purity 100%:Method B: 8.00min. purify 100%.

2-((5-(4-acetylpiperazin-1-yl)pyridin-2-yl)ammo)-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidine-carbonitrile(34)

To a solution of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(315mg. 1.20 mmol) in 2-methoxyethanol (4 mL) were added tert-butyl(E)-(5-(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(350 mg, 1.00 mmol) and NaOH (82.0 mg, 2.40 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM :MeOH=90:10 with consecutive addition of 32% aqueous ammonia, up to3 %). The solid was washed with DCM and MeOH, then filtered to give 34as a pale yellow solid (157 mg, 35%). 1_(H) NMR (DMSO-d₆) δ2.04 (s,311), 2.40 (s, 3H), 2.87 (s, 3H). 3.10 (t, 2H, J 5.0), 3.16 (t, 2H, J5.0), 3.58 (t, 4H, J 5.0), 7.46 (dd, 1H, J 9.5 & 3.0), 7.90 (d, 1H, J9.0), 8.06 (d, 1H, J 3.0), 8.26 (q, 1H. J 3.0), 8.75 (s, 1H), 10.33 (s,1H). HRMS (ESI): m/z 450.1844 [M+H]⁺; calcd. for C₂₁H₂₄N₉OS⁺ [M+H]⁺450.1819. Anal. RP-HPLC Method A: t_(R) 10.34 mm, purity>97%; Method B:t_(R) 8.769 min, purity>98%.

1-(4-(6-((5-Fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(35)

To a solution of crude 1(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (1.08g, 2.06 mmol) in 2-methoxyethanol (6 mL) were added(E)-3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(500 mg, 2.06 mmol) and NaOH (164.4 mg, 4.11 mmol). The reaction mixturewas heated at 180° C. for 150 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM :MeOH=90.10 with consecutive addition of 32% aqueous ammonia, up to1%). The solid was washed with DCM and MeOH, then filtered to give 35 asa reddish brown solid (400 mg, 44%). 1_(H) NMR (DMSO-d₆) δ2.04 (s, 3H,),2.47 (d, 3H, J 2.5), 2.87(d, 3H, J 4.3), 3.05 (t, 2H, J 5.0), 3.11 (t,2H, J 5.0), 3.58 (app q, 4H, J 6.0), 7.43 (dd, 1H, J 9.0 & 3.0), 7.98(d, 1H, J 9.0), 8.02 (d. 1H, J 3.0), 8.12 (q, 1H, J 4.5), 8.43 (d, 1H, J3.5), 9.59 (s, 1H). HRMS(ESI) m/z 443.1800 [M+H]⁺; calcd. forC₂₀H₂₄FN₈OS⁺ [M+H]⁺ 443.1772. Anal. RP-HPLC Method A: t_(R) 9.75 min.purity>95%; Method B: t_(R) 7.77 min. purity>95%.

N,4-dimethyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazole-2-amine(36)

To a solution of crude1-(5-(4-aminopiperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(266mg, 1.20 mmol) in 2-methoxyethanol (4 mL) were added(E)-3-(dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(225 mg, 1.00 mmol) and NaOH (82.0 mg, 2.40 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=96:4). The solid was washed with DCM and MeOH, and thenfiltered to give 36 as a pale yellow solid (69.0 mg. 18%). 1_(H) NMR,DMSO-d₆) δ2.47 (s, 3H), 2.86(d, 2H, J 5.0), 3.08 (t, 4H, J 5.0), 3.74(t, 4H, J 5.0), 6.92 (d, 1H, J 5.0), 7.41 (dd, 1H, J 9.0 &3.0). 7.99 (d,1H, J 3.0), 8.06 (q, 1H, J 5.0 & 4.5), 8.08 (d, 1H, J 9.0), 8.33 (d, 1H,J 5.0), 9.26 (s, 1H). MS (ESI): m/z 384.1674 [M+H]⁺; calcd. forC₁₈H₂₁N₇OS⁺ [M+H]⁺ 384.1601.Anal. RP-HPLC Method A: t_(R) 10.08 min.purity>99%; Method 8: t_(R) 7.98 min, purity>99%.

4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-((5-morpholinopyridin-2-yl)amino)pyrimidine-5-carbonitrile(37)

To a solution of crude1-(5-(A-aminopiperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (222mg, 1.00 mmol) in 2-methoxyethanol (4 mL) were added tert-butyl(E)-(5-(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(350 mg, 1.00 mmol) and NaOM (68.0mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=97:3 ), washed with DCM and MeOH, then filtered to give 37 as apale yellow solid (126 mg, 31%). 1_(H) NMR (DMSO-d₆) δ 2.42 (s, 3H),2.89 (d, 3H, J 4.5), 3.12 (t, 4H, J 5.0), 3.75 (t, 4H, J 5.0), 7.42 (dd,1H, J 9.0 & 3.0), 7.93 (d, 1H, J 9.0), 8.04 (d, 1H, J 3.0), 8.23 (dd,1H, J 9.0 & 4.5), 8.73 (s, 1H), 10.28 (s, 1H). HRMS (ESI): m/z 409.1549[M+H]⁺; calcd. for C₁₉H₂₀N₈OS⁺ [M+H]⁺ 409.1554.Anal. RP-HPLC Method A:t_(R) 10.88 min, purity>98%, Method B: t_(R) 8.60 min, purity>97%.

5-(5-Fluoro-2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(38)

To a solution of crude1-(5-(4-aminopiperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (332mg. 1.5 mmol) in 2-methoxyethanol (4 mL) were added(E)-3-dimethylamino)-2-fluoro-1-(4-methyl-2-(methoxyamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (60.0 mg, 1.5 mmol). The reaction mixturewas heated at 180° C. for 90 min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=94:6) to give 38 as a purple solid (138 mg, 34%). 1_(H) NMR(DMSO-d₆) δ 2.48 (d, 3H, J 2.0), 2.87 (d, 3H, J 4.5), 3.08 (t, 4H, J5.0), 3.75 (t, 4H, J 5.0), 7.39(dd, 1H, J 9.0 & 3.0), 7.97 (d, 1H, J9.0), 7.99 (d, 1H, J 3.0), 8.12 (q, 1H, J (4.5), 8.42 (d, 1H, J 3.5),9.52 (s, 1H). HRMS (ESI): m/z 402.1524 [M+H]⁺; calcd. for C₁₈H₂₁FN₇OS⁺[M+H]⁺ 402.1507. Anal. RP-HPLC Method A: t_(R) 9.95 min, purity 100%;Method B: t_(R) 7.97 min, purity 100%.

5-(2-((5-(4-Benzylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(39)

To a solution of crude1-(5-(4-benzylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetatetrifluoroacetate (640 mg, ≤0.999 mmol) in 2-methoxyethanol (3 mL) wereadded(E)3-(Dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(390 mg, 1.20 mmol) and NaOH (80.0 mg, 2.03 mmol). The reaction mixturewas heated at 140° C. under microwave irradiation for 45 min, cooleddown to room temperature and filtered. The solids were washed with MeOH(15 ml ) and DCM (30 mL), and purified by chromatography (silica gel,DCM ramping to DCM:MeOH=95:5) to give 39 as a yellow solid (64.0 mg,14%, an overall yield for two steps), m.p. 275-276° C. 1_(H) NMR(DMSO-d₆) δ 2.46 (s, 3H), 2.52 (t, 4H, J 4.0), 2.86 (d, 3H, J 4.0), 3.12(t, 4H, J 3.6), 3.53 (s, 2H), 6.91 (d, 1H, J 4.4), 7.24-7.28 (m, 1H),7.33-7.36 (m, 4H), 7.38 (dd, 1H, J 7.2 & 2.4), 7.96 (d, 1H, J 2.4), 8.03(q, 1H, J 4.0), 8.06 (d, 1H, J 7.6), 8.32 (d, 1H, J 4.4), 9.18 (s, 1H).HRMS (ESI): 473.2252 ([M+H]⁺); calcd. for C₂₅H₂₉N₈S⁺ ([M+H]⁺) 473.2230.Anal. RP-HPLC Method A: t_(R) 7.51 min. purity>99%; Method B: t_(R) 6.26min, purity>99%.

2-((5-(4-Benzylpiperazin-1-yl)pyridin-2-yl)amino)-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidine-5-carbonitrile(40)

To a solution of crude1-(5-(4-benzylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(640 mg, ≤0.999 mmol) in 2-methoxyethanol (3 mL) were added tert-butyl(E)-5-(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(350 mg, 0.999 mmol) and NaOH (80.0 mg, 2.03 mmol). The reaction mixturewas heated at 140° C. under microwave irradiation for 45 min, cooleddown to room temperature and filtered. The solids were washed with MeOH(15 mL) and DCM (30 mL), and purified by chromatography (silica gel, DCMramping to DCM:MeOH=95:5) to give 40 as a yellow solid (177 mg, 36%, anoverall yield for two steps and calculated based on 6). m.p. 255-256° C.1_(H) NMR (DMSO-6 ₆) δ 2.40 (s, 3H), 2.51 (t, 4H, J 3.6), 2.87 (d, 3H, J3.2), 3.14 (t, 4H, J 3.6), 3.51 (s, 2H), 7.23-7.28 (m, 1H) 7.32-7.35 (m,4H), 7.40 (dd, 1H, J 7.2 & 2.4), 7.87 (d, 1H, J 7.2), 8.03 (d, 1H, J2.4), 8.23 (q, 1H, J 3.2), 8.73 (s, 1H), 10.29 (s, 1H). HRMS (ESI):498.2188 [M+H]⁺; calcd. for C₂₆H₂₈N₉S⁺ [M+H]⁺ 498.2183. Anal. RP-HPLCMethod A: t_(R) 8.38 min, purity>95%: Method B: t_(R) 6.75 min.purity>96%.

5-(2-((4-(4-Benzylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(41)

To a solution of crude 1-(4-(4-benzylpiperazin-1-yl)phenyl)guanidinetrifluoroacetate (530 mg, ≤1.71 mmol) in 2-methoxyethanol (3 mL) wereadded(E)-3-(dimethylamino)-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(200 mg, 0.888 mmol) and NaOH (73.0 mg, 1.82 mmol). The reaction mixturewas heated at 160° C. under microwave irradiation for 30 min, cooleddown to room temperature and concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel. DCM ramping toDCM:MeOH=95:5) to give 41 as a yellow solid (60.0 mg. 14%). m.p.212-213° C. 1_(H) NMR (DMSO-d₆) δ 2.44 (s, 3H), 2.50 (t, 4H, J 4.0),2.85 (d, 3H, J 3.6), 3.05 (t, 4H, J 4.0). 3.51 (s, 2H). 6.81 (d, 1H, J4.4), 6.85 (d, 2H, J 7.6), 7.23-7.29 (m, 1H), 7.31-7.35 (m, 4H) 7.57 (d,2H, J 7.2), 7.98 (q, 1H, J 4.0), 8.26 (d, 1H, J 4.4), 9.13 (s, 1H). HRMS(ESI): 472.2295 [M+H]⁺; calcd. for C₂₆H₃₀N₇S⁺ [M+H]⁺ 472.2278 Anal.RP-HPLC Method A: t_(R) 8.11 mm. purity>99%; Method B: t_(R) 6.62 min,purity>99%.

2-((4-(Benzylpiperazin-1-yl)phenyl)amino)-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidine-5-carbonitrile(42)

To a solution of crude 1-(4-(4-benzylpiperazin-1-yl)phenyl)guanidinetrifluoroacetate (353 mg, ≤1.14 mmol) in 2-methoxyethanol (3 mL) wereadded tert-butyl (E)-(5(2-cyano-3-(dimethylamino)acryloyl)-4-methylthiazol-2-yl)(methyl)carbamate(200 mg, 0.571 mmol) and NaOH (45.7 mg, 1.14 mmol). The reaction mixturewas heated at 160 under microwave irradiation for 30min, cooled down toroom temperature and concentrated under reduced pressure. The residuewas purified by chromatography (silica gel, DCM ramping toDCM:EtOAc=1:3) and recrystallized with DCM and MeOH to give 42 as ayellow solid (80.0 mg, 28%), m.p. 220-221° C. 1_(H) NMR (DMSO-d₆) δ 2.34(s, 3H), 2.50 (t, 4H, J 4.0), 2.86 (d, 3H, J 3.6), 3.08 (t, 4H, J 4.0),3.51 (s, 2H), 6.89 (d, 2H, J 7.2), 7.23-7.29 (m, 1H), 7.31-7.35 (m, 4H),7.48 (d, 2H, J 6.4), 8.17 (q, 1H, J 3.6), 8.67 (d, 1H, J 4.0), 10.03(s,1H). HRMS (ESI): 497.2206 [M+H]⁺; calcd. for C₂₇H₂₉N₈S⁺ [M+H]⁺ 497.2230Anal. RP-HPLC Method A: t_(R) 8.36 min. purity>96%; Method B: t_(R)10.18 min, purity>95%.

N, N,4-Trimethyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(43)

To a suspension of1-(4-(6-((4-(2-(Dimethylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(100 mg, 0.23 mmol) in methanol HCl (32%, 5 mL) was added and re flexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to EtOAc:MeOH:NH₄OH)=90:10:1) togive 43 as a yellow solid (83 mg, 92%). m.p. 210-211° C. 1_(H) NMR(DMSO-d₆) δ 1.74 (br, 1H), 2.57 (s, 3H), 3.06 (t, 4H, J 5.5), 3.11 (t,4H, J 3.5), 3.18 (s, 6H₂), 6.84 (d, 1H, J 5.5), 7.33 (dd, 1H, J 9.0 &3.0), 7.79 (s, 1H), 7.99 (d, 1H, J 3.0), 8.28 (d, 2H, J 9.5), 8.31 (d,1H, J 5.5). HRMS (ESI): m/z 397.1925 [M+H]⁺;calcd. for C₁₉H₂₅N₈S⁺ [M+H]⁺397.1917. Anal. RP-HPLC Method A: t_(R) 8.39 min. purity>95%; Method B:t_(R) 7.42 min, purity 100%.

5-(5-Fluoro-2-((5-(piperazin-1-yl)pyridin-2-yl)amrno)pyrimidin-4-yl)-N,N,4-trimethylthiazol-2-amine(44)

To a suspension of1-(4-(6-((4-(2-(dimethylamino)-4-methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(100 mg, 0.22 mmol; in methanol HCl (32%, 3 mL) was added and reflexedovernight, The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to DCM:MeOH:NH₄OH=90:10:1) togive 44 as a yellow solid (45.4 mg, 50%). 1_(H) NMR (CDCl₃) δ 2.58 (d,3H, J 2.0,), 3.05 (t, 4H, J 6.0), 3.09 (t, 4H, J 6.0), 3.17 (s, 6H),7.30 (dd, 1H, J 9.0 & 3.0), 7.98 (br s, 1H), 8.00 (s, 1H), 8.19 (d, 1H,J 9.0), 8.23 (d, 1H, J 1.5). HRMS (ESI): m/z 415.1821 [M+H]⁺; calcd. forC₁₉H₂₄FN₈S⁺ [M+H]⁺ 415.1823. Anal. RP-HPLC Method A: t_(R) 9.00 mm.purity>98%; Method B: t_(R) 7.30 min. purity>99%.

N,N,4-trimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(45)

To a solution of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(2-(dimethylamino)-4-methylthiazol-5-yl)prop-2-en-1-one(239 mg, 100 mmol) and NaOH (80.0 mg, 2.00mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=90:10 with constant addition of 0.5 ml of 32% ammonia) to give45 as a yellow solid (40.0 mg, 10%). 1_(H) NMR (CDCl₃) δ 2.36 (s, 3H),2.57 (s, 3H), 2.59 (t, 4H, J 5.0), 3.17 (br s, 10H), 6.84 (d, 1H, J5.5), 7.33 (dd, 1H, J 9.0 & 3.0), 7.96 (s, 1H), 8.02 (d, 1H, J 3.0),8.28 (d, 1H, J 9.0). 8.33 (d, 1H, J 5.5). HRMS (ESI): m/z 411.2048[M+H]⁺; calcd. for C₂₀H₂₇N₈S⁺ [M+H]⁺ 411.2074. Anal. RP-HPLC Method A:t_(R) 8.77 min, purity>99%; Method B: 3.24 min. purity>95%

5-(5-Fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,N,4-trimethylthiazol-2-amine(46)

To a solution of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(2-(dimethylamino)-4-methylthiazol-5-yl)prop-2-en-1-one(257 mg, 1.90 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom Temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=95.5 with constant addition of 0.5 ml of 32% ammonia) to give46 as a reddish brown solid (61.0 mg, 14%). 1_(H) NMR (CDCl₃) δ 2.36 (s,3H), 2.57(d, 3H, J 2.5), 2.59 (t, 4H, J 5.0), 3.17 (s, 10H), 7.30(dd,1H, J 9.0 & 3.0), 8.33 (d, 1H, J 2.0), 8.18 (d, 1H, J 9.0), 8.23 (d, 1H,J 3.5). HRMS (ESI): m/z 429.1981 [M+H]⁺; calcd. for C₂₀H₂₆FN₈S⁺ [M+H]⁺429.1980. Anal. RP-HPLC Method A: t_(R) 8.99 min. purity>96%; Method B:t_(R) 7.30 min. purity>98%.

5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(47)

To a solution of crude1-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (524 mg. 2.00 mmol) in 2-methoxyethanol (3 mL) wereadded(E)-3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=90:10 with constant addition of 0.5 ml of 32% ammonia) to give47 as a brown solid (76 mg, 17.2%) 1_(H) NMR (DMSO-d₆) δ 1.50 (q, 2H, J11.0), 1.84 (d, 3H, J 11.0), 2.21 (s, 7H), 2.47 (s, 3H, thiazole-CH3),2.64 (t, 2H, J 11.0), 2.86 (t, 3H, J 3.5), 3.63 (d, 1H, J 11.0), 7.39(appd, 1H, J 7.0), 7.92 (d, 1H, J 9.0), 7.98 (s, 1H), 8.10( 1H, J 4.0),8.41 (s, 1H), 9.43 (s, 1H). HRMS (ESI): m/z 443.2136 [M+H]⁺; calcd. forC₃₁H₂₈FN₈S⁺ [M+H]⁺ 443.2133. Anal. RP-HPLC Method A: t_(R) 9.12 min,purity>95%; Method B: t_(R) 2.84 min, >99%

1-(4-(6-((4-(2-(Dimethylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-y1)ethan-1-one(48)

To a solution of etude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(525 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(2-(dimethylamino)-4-methylthiazol-5-yl)prop-2-en-1-one(239 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, EtOAc tamping toPE:EtOAc=100%) to give 48 as a yellow solid (100 mg, 10%). m.p. 234-235°C. 1_(H) NMR (CDCl₃) δ 2.12 (s, 3H), 2.55 (s, 3H), 3.08 (t. 211, J 5.0),3.11 (t, 2H, J 5.0), 3.15 (s, 6H), 3.61 (t, 2H, J 5.0), 3.77 (t, 2H, J4.5), 6.83 (d, 1H, J 5.5), 7.32 (dd, 1H, J 9.0 & 3.0), 8.08 (d, 1H, J3.0). 8.32 (d, 1H, J 9.0), 8.37 (d, 1H, J 5.5), 8.73 (s, 1H). HRMS(ESI): m/z 439.2040 [M+H]⁺;calcd. for C₂₁H₂₇OS⁺ [M+H]⁺ 439.2023. Anal.RP-HPLC Method A: t_(R) 10.06 min. purity>97%; Method B: t_(R) 8.62 min.purity >96%

1-(4-(6-((4-(2-(Dimethylamino)-4-methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(49)

To a solution of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluroacetate (525mg, 2,00 mmol) 2-methoxyethanol (3 mL) were added(E)-3-dimethylamino)-1-(2-dimethylamino)-4-methylthiazol-5-yl)-2-fluoroprop-2-en-1-one(257 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixtureheated at 180°C. for 1h min under microwave irradation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM rampingDCM:MeOH=95:5 with constant addition of 0.5 ml of 32% ammonia) to give49 as a reddish brown solid (148 mg, 32%). 1_(H) NMR (CDCl₃) δ 2.14 (s,3H) 2.57 (d, 3H, J 2.5), 3.08 (t, 2H, J 10,0), 3.11, (t. 2H, J 10.0 )3.17 (s, 6H), 3.63 (t,2H, J 10.0), 3.78 (t,2H, J 10.0), 7.31 (dd, 1H, J9.0 & 3.0) 8.04 (d, 1H, J 3.0), 8.23 (d, 1H, J 9.0), 8.25 (app d, J 3.01H), 8.31 (s, 1H, NH). HRMS (ESI): m/z 457.925 [M+H]⁺; calcd. forC₂₁H₂₆FNOS⁺ [M+H]⁺ 457 929. Anal. RP-HPLC Method A: t_(R) 10,43 min,purity >95%; Method B: t_(R) 8.29 min, purity >95%.

5-(5-Fluoro-2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-N,N4-trimethylthiazol-2-amine(50)

To a solution of crude 1-(5-morpholinopyridin-2-yl) guanidinetrifluoroacetate trifluoroacetate (443 mg, 2.00 mmol) in2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(2-(dimethylamino)-4-methylthiazol-5-yl1-2-fluoroprop-2-en-1-one(257 mg 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=95:5 with constant addition of 0.5 ml of 32% ammonia) to give50 as a reddish brown solid (166 mg, 40%). 1_(H) NMR (CDCl₃). δ 2.58 (s,3H), 3.11 (t, 4H, J 5.0), 3.17 (s, 6H), 3.89 (t, J 4.5), 7.29 (dd, 1H J9.0 & 2.5), 8.01 (d, 1H, J 3.0), 8.05 (s, 1H), 8.21 (d, 1H, J 9.0), 8.23(d, 1H, J 3.5). HRMS (ESI): m/z 416.166.5 [M+H]⁺; calcd. forC₁₉H₂₃FN_(&)OS⁺ [M+H]⁺ 416.1.663. Method A: t_(R) 10.60 min,purity >95%; Method B: t_(R) 8.52 min, purity >97%.

5-(5-fluoro-2-((5-(piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(51)

To a solution of crude 1-(5-(piperidin-1-yl)pyridin-2-yl)guanidine (439mg, 2.00 mmol) in 2-(methylamino)thiazol-5-yl)prop-2-en-1-one (243 mg,1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction was heated at180° C. for 1h under microwave irradiation, cooled down to roomtemperature, and then concentrated under reduced pressure. The residuewas purified by chromatography (silica gel, DCM ramping toDCM:MeOH=94:6) to give 51 as a reddish brown solid (66 mg, 17%). 1_(H)(dd, 1H, J 9.0 & 2.5), 7.93 (d, 1H, J 9.0), 7.97 (D, 1H, J 2.5), 8.10(d, 1H, J 5.0), 8.41 (d, 1H j 3.5), 9.45 (s, 1H), HRMS (ESI): m/z400.1710 [M+H]⁺; calcd. for C₁₉H₂₃FN₇S⁺ 400.1714. Anal. RP-HPLC MethodA: t_(R) 12.08 min, purity >95%; Method B: t_(R)8.70 min. >98%.

5-(5-fluoro-2-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(52)

To a solution of crude1-(5-(4-(methylsolfonyl)piperazin-1-yl)pyridin-2-yl)guanidine (596 mg,2.00 mmol) 2-methoxyethanol (3 mL) were added((E)-3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (80.0 mg, 2.99 mmol.) The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified chromatography (silica gel, DCM ramping toDCM:MeOH=94:6 to give 52 a reddish brown solid (2.9 mg, 6%). 1_(H) NMR(DMSO-d₆) δ 2.88 (d, 3H, J 4.5), 2.94 (s, 3H), 3.23 (t, 4H, J 5.0,) 3.27(t, 4H J 5.5), 3.33 (s, 3H), 7.52 (app d, 1H, J 8.0), 7.6 (d, 1H, J9.0), 8.02(d, 1H J 2.5) 8.15 (d, 1H, J 4.5), 8.44 (d, 1H, J 3.5), 9.69(s, 1H). HRMS (ESI): m/z 479.1441 [M+H]⁺; calcd. for C₁₉H₂₄FN₈O₂S⁺[M+H]⁺ 479,1442. Anal. RP-HPLC Method A: t_(R) 94%; Method B: t_(R) 8.08min, >97%.

5-(2-((5-(1,4-diazepan-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(53)

To a solution of crude 1-(5-(1,4-diazepan-1-yl)pyridin-2-yl)guanidinedi(2,2,2-trifluoroacetate) (469 mg, 2,00 mmol) 2-methoxyethanol (3 mL)were added((E)-3-(dimethylamino)-2fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(243 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 ) mmol). The reactionmixture was heated at 180° C. for 1h under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=90:10) to give 53 as an orange solid (40 mg, 10%). 1_(H) NMR(DMSO-(d₆) δ 1.75-1.80 (m, 2H), 2.45 (4, 314,12.0), 2.62 (t :214, J6.0), 2.85 (t, 2H, J 5.5), 3.45 (t, 2H, J 5.0), 3.53 (t, 2H, J 6.0),7.13 (dd,1H, J 9.0 & 3.0),7.78 (s, 1H), 7.79 (d, 1H, J 4.5), 8.08(q, 1H,J 4.5), 8.37 (d, 1H, J 3.5), 9,21 (s, 1H). HRMS (ESI): m/z 415.1821[M+H]⁺; calcd for C₁₉H₂₄FN₈S⁺ [M+H]⁺ 415.1823. Anal. RP-HPLCMethod A:t_(R) 8.72 min, purity >98%; Method B: t_(R) 2.84 min, 100%.

5-(5-fluoro-2-(pyridin-2-ylamino)pyrimidin-4-yl)-N,4-dimethylthiazol-2-amine(54)

To a solution crude 1-(pyridin-2-yl)guanidine 2,2,2-trifluoroacetate(409 mg, 3.00 mmol) in 2-methoxyethanol (8 mL) were added((E)-3-(dimethylamino)-2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one(487 mg, 2.00 mmol) and NaOH (160 mg, 4.00 mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM ramping toDCM:MeOH=98:2) to give 54 as an orange solid (70 mg, 22%). 1_(H) NMR(DMSO-d₆) 2.89 (d, 3H, J 4.5), 3.34 (s, 1H), 6.99 (m, 2H), 7.75 (t, 1H,J 7.5), 8.14 (m, 2H), 8.29 (d, 1H, J 3.0). 8.50 (d, 1H, J 3.0), 9.79 (s,1H). HRMS (ESI): m/z 317.0989 [M+H]⁺; calcd. for C₁₄H₁₄FN₆S⁺ [M+H]⁺317.0979. Anal. RP-HPLC Method A: t_(R) 10.45 min, purity>97%; Method B:t_(R) 9.24 min, purity >98%.

N-isopropyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(55)

To a suspension of1-(4-(6-((4-(2-(isopropylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(143 mg, 0.32 mmol) in methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified bychromatography (silica gel, DCM ramping to DCM MeOH:NH₂OH=90:10:1) togive 55 as a yellow solid (120 mg, 92%,). 1_(H) NMR (DMSO-d₆) δ 1.19 (d,6H, J 6.5, CH(CH₃)₂), 2.46 (s, 3H), 2.87 (t, 4H, J 5.0), 3.03 (t, 4H, J5.5), 3.80-3.87 (m, 1H, CH), 6.90 (d, 1H, J 5.5), 7.37 (dd, 1H, J 9.0 &3.0), 8.00 (d. 1H, J 3.0), 8.05 (d, 2H, J 7.5), 8.08 (d, 1H, J 9.0),8.33 (d, 1H, J 5.5), 9.29 (s, 1H) HRMS (ESI): m/z 411.2072 [M+H]⁺;calcd. for C₂₀H₂₇N₈RS⁺ [M+H]⁺ 411.2074. Anal. RP-HPLC Method A: t_(R)8.43 min, purity >96%; Method B: t_(R) 7.61 min. purity 99%.

N-isopropyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(56)

To a solution of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol5-yl)prop-2-en-1-one (253 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol).The reaction mixture was heated at 180° C. for 1h min under microwaveirradiation, cooled down to room temperature, and then concentratedunder reduced pressure. The residue was purified by chromatography(silica gel, DCM ramping to DCM:MeOH=94:6 ) to give 56 as a yellow solid(131 mg, 31%). 1_(H) NMR (DMSO-d₆) δ 1.19 (d, 6H, J 6.5,), 2.22 (s, 3H),2.46 (s br, 7H), 3.11 (t, 4H, J 5.0), 3.81-3.85 (m, 1H), 6.90 (d, 1H, J5.5), 7.38 (dd, 1H, J 9.0 & 3.0), 8.00 (d, 1H, J 3.0), 8.04 (d, 2H, J7.5), 8.08 (d, 1H, J 9.0), 8.34 (d, 1H, J 5.5), 9.32 (s, 1H). HRMS(ESI): m/z 425.2235 [M+H]⁺; calcd. for C₂₁H₂₉N₈S⁺ [M+H]⁺ 425.2230. Anal.RP-HPLC Method A: t_(R) 8.563 min. purity 100%; Method 8: t_(R) 7.73min, purity 100%.

1-(4-6-((4-(2-(isopropylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1yl)ethan-1-one(57)

To a solution of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(525 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) were added(E)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one(253 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h min under microwave irradiation, cooleddown to room temperature, and then concentrated under reduced pressure.The residue was purified by chromatography (silica gel, DCM ramping, toDCM:MeOH=96:4) to give 57 as an orange solid (80 mg, 18%, 1_(H) NMR.(DMSO-d₆) δ 1.19 (d, 6H, J 6.5), 2.05 (s, 3H), 2.46 (s, 3H), 3.06 (t,2H, J 5.0), 3.13 (t, 2H, J 5.0), 3.59 (q 4H, 5.5), 3.81-3.85 (m, 1H),6.91 (d, 1H, J 5.5), 7.40 (dd, 1H, J 9.0 & 3.0), 8.02 (d, 1H, J 3.0),8.05 ( 2H, J 7.5), 8.10 (d, 1H, J 9.0), 8.33 (d, 1H, J 5.5), 9.31 (s,1H). HRMS (ESI): m/z 453,2187 [M+H]⁺; calcd. f or C₂₂H₂₉N₈OS⁺ [M+H]⁺453.2180. Anal. RP-HPLC, Method A: t_(R) 10.03 min, purity 100%, MethodB: t_(R) 8.85 min, purity >99%.

N-isopropyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(58)

To a solution of crude (5-molpholinopyridin-2-yl)guanidinetrifluoroacetate (443 mg, 2.00 mmol) in 2-methoxyethanol (3 mL) wereadded (E)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (253 mg, 1.00 mmol) and NaOH (80.0mg, 2.00 mmol). The reaction mixture was heated at 180° C. for 1h minunder microwave irradiaton, cooled down to room temperature, and thenconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=96:4) to give 58 asa yellow solid. (200 mg, 48%,). 1_(H) NMR (DMSO-d₆) δ 1.19 (d, 6H, J6.5), 2.45 (s,3H), 3.09 (t, 4H, J 4.0), 3.76 (t, 4H, J 4.0), 3.81-3.85(m, 1H), 6.90 (d, 1H, J 5.5), 7.39 (dd, 1H, J 9.0 & 3.0), 7.01 (d, 1H, J2.5), 8.05 (d, 2H J 7.5), 8.10 (d, 1H, J 9.0), 8.34 (d, 1H, J 5.5), 9.33(s, 1H). HRMS (ESI): m/z 412,1912 [M+H]⁺; calcd. for C₂₀H₂₆N₇OS⁺ [M+H]⁺412.1914. Anal. RP-HPLC Method A: t_(R) 10.21 min, purity 100%; MethodB: t_(R) 9.08 min, purity >99%.

5-(2-((5-(1,4-diazepan-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-isopropyl-4-methylthiazol-2-amine(59)

To a solution of crude 1-(5-(1,4diazepan-1-yl)pyridin-2yl)guanidinedi(2,2,2-trifluoroacetate) (469 mg, 2.00 mmol) in 2-methoxyethanol (3mL) were added(E)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one(253 mg, 1.00 mmol) and NaOH (80.0 mg, 2.00 mmol). The reaction mixturewas heated at 180° C. for 1h under microwave irradiation, cooled down toroom temperature, and then concentrated under reduced pressure. Theresidue was purified by chromatography (silica gel, DCM rampingDCM:MeOH=90:10) to give 59 as an range solid (114 mg, 34%). 1_(H) NMR(DMSO-d₆) δ 1.19 (d, 6H, J 6.5), 2.04-2.09 (m, 2H), 2.47 (s, 3H), 3.16(s, 1H, J 5.5), 3.27 (s, 2H, J 5.0), 3.50 (d, 2H, J 6.0), 3.70 (t, 2H, J5.0), 3.80-3.86 (m, 1H), 6.87 (d, 1H, J 5.5), 7.24 (dd, 1H, J 9.0 &3.0), 7.89 (d, 1H, J 3.0), 8.03 (d, 2H, J 5.5), 8.05 (d, 1H. J 4.0),8.31 (d, 1H, J 5.5), 8.75 (s 1H), 9.15 (s, 1H). HRMS (ESI): m/z 425.2231[M+H]⁺; calcd. for C₂₁H₂₉N₈S⁺ [M+H]⁺ 425.2230 Anal. RP-HPLC Method A:t_(R) 8.48 min, purity >95%. Method B: t_(R) 7.69 min, >98%.

N-Cyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl) amino)pyrimidin-4-yl) thiazol-2-amine (60)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 mg, 1.00 mmol) 7-methoxy ethanol (3 mL) was addedNaOH (80,0 mg, 2.00 mmol). The reaction mixture was heated 180° C. undermicrowave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=92:8) andrecrystallised with DCM and MeOH to give 60 as a dark yellow solid (70.0mg, 16%). m.p. 210-213° C. 1_(H) NMR (DMSO-d₆) 1.49-1.68 (m, 7H),1,89-1.94 (m, 2H) 2.46 (s, 3H), 2.85 (t, 4H, J 4.5), 3.02 (t, 4H, J5.0), 3.98 (m, 1H), 6.90 (d, 1H, J 5.5), 7.36 (dd, 1H, J 9.0 & 3.0),7.98 (d, 1H, J 3.0), 8.07 (d, 1H, J 9.0), 8.18 (d, 1H, J 7.0), 8.33 (d,1H, J 5.5), 9.33 (s, 1H). HRMS (ESI): m/z 437.2222 [M+H]⁺; calcd. forC₂₂H₂₉N₈S⁺ [M+H]⁺ 437,2230Anal. RP-HPLC M.thod A: t_(R) 10.10 min,purity >99%; Method B: t_(R) 7.78 min, purity >99%.

N-cyclopentyl-5-(5-fluoro-2-((5-(piperazin-1yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine(61)

To a mixture or crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and((E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (297 mg, 1.00 mmol) in 2-methoxyethanol (3 mL) was added NaOH(80.0 mg, 2.00 mmol). The reaction mixture was heated at 180° C. undermicrowave irradiation for 1 h,, cooled to room temperature andconcentrated under reduced pressure. The residue was purifiedchromatography (silica gel, DCM ramping to DCM:MeOH:NH₄OH=90:10:1) togive 61 as a yellow solid (101 mg, 22%). 1_(H) NMR (DMSO-d₆) 1.54-1.57(m, 4H), 1.66-1.69 (m, 2H), 1.92-1.95 (m, 2H), 2.47 (s, 3H) 3.26 (t, 4H,J 2.5), 3.31 (t, 4H, J 2.5), 3.95 (m, 1H, cyclopentane-CH), 7.46 (dd,1H, J 9.0 & 3.0), 8.00 (d, 1H, J 9.0), 8.05 (d, 1H, J 3.0), 8.25 (d, 1H,J 7.0) 8.42 (d, 1H, J 3.5), 8.84 (d, 1H, J 3.5), 9.57 (s, 1H). HRMS(ESI): m/z 455.2139 [M+H]⁺; calcd. for C₂₂H₂₈FN₈S⁺ [M+H]⁺ 455,2136,Anal, RP-HPLC Method A: t_(R) 9.55 min, purity 100%; Method B: t_(R)7.86 min, purity 100%.

N-cyclopentyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethylthiazol-2-amine(62)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one(3.53 mg, 1.00 mmol) in 2-methoxyethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH:NH₄OH=90:10:1) to give 62 as an orangesolid (260 mg, 53%). 1_(H) NMR (DMSO-d₆) δ 1.50-1.59 (m, 4H), 1.65-1.70(m, 2H), 1.92-1.97 (m, 2H), 2.26 (s, 1H), 2.84 (t, 4H, J 5.0), 3.02 (t.4H, J 5.0), 3.96 (m, 1H), 6,96 (d, 1H, J 6.0), 7.37 (dd, 1H, J 9.0 &3.0), 7.98 (d, 1H, J 4.0). 7.99 (d, 1H, J 1.0). 8.50 (d, 1H, J 5.5),8.59 (d, 1H, J 6.5), 9.59 (s, 1H,). HRMS (ESI): m/z 491.1952 [M+H]⁺;calcd. for C₂₂H₂₆F₃N₈S⁺ [M+H]⁺ 491.1948. Anal. RP-HPLC Method A: t_(R)10.31 min, purity 100%; Method B: t_(R) 8.30 min, >98%.

N-Cyclopentyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(63)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) wasadded NaOH (80.0 mg, 2.00 mmol). The reaction mixture was heated at 180°C. under microwave irradiation for 1 h. cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=93:7) andrecrystallised with DCM and MeOH to give 63 as a yellow solid (100 mg,22%). m.p. 202-205° C. 1_(H) NMR (CDCl₃) δ 1.51-1.71 (m, 6H), 1.99-2.05(m, 2H), 2.35 (s, 3H), 2.48 (s, 3H), 2.62 (t, 4H, J 5.0), 3.14 (t, 4H, J5.0), 3.79 (br, 1H),), 6.03 (br, 1H), 6.78 (d, 1H, J 5.0), 7.27 (dd, 1H,J 9.0 & 3.0), 7.96 (d, 1H, J 3.0), 8.10 (s, 1H), 8.21 (d, 1H, J 9.0),8.29 (d, 1H, J 5.0). HRMS (ESI): m/z 451.2396 [M+H]⁺; calcd. forC₂₃H₃₁N₈S⁺ 451.2387. Anal. RP-HPLC Method A: t_(R) 9.56 min,purity >99%; Method B: t_(R) 9.50 min. purity >98%.

N-cyclopentyl-5-(5-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine(64)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(234 mg, 1.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(148 mg, 0.50 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (40.0 mg,1.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH:NH₄OH=94:6:0.5) and recrystallised withEt₂O to give 64 as a dark brown solid (100 mg, 5%). m.p. 207-209°C.1_(H) NMR. (CDCl₃) δ 1.52-1.79 (m, 6H), 1.06-2.12 (m, 2H), 2.38 (s, 3H)2.55 (s, 3H), 2.63 (t, 4H, J 5.0) 3.18 (t, 4H, J 5.0), 3.84 (m, 1H),5.56 (d, J 6.0, 1H), 7.31 (dd, 1H, J 9.0 & 3.0), 7.82 (s, 1H), 7.99 (d,1H, J 3.0), 8.18 (d, 1H, J 9.0), 8.23 (d, 1H, J 3.5). HRMS (ESI): m/z469.2287 [M+H]⁺; calcd. for C₂₃H₃₀FN₈S⁺ [M+H]⁺ 469.2293, Anal. RP-HPLCMethod A: t_(R) 10.37 min, purity >97%; Method B: t_(R) 8.42 min, >98%.

N-cyclopentyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine(65)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(148 mg, 0.50 mmol) 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction. mixture was heated at 180° C. under microwaveirradiation for 1 h., cooled to temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=94:6) to give 65 as a brown solid (30 mg,6%). 1_(H) NMR (DMSP-d₆) δ 1.56-1.59 (m, 4H), 1.67-1.69 (m, 2H),1.93-1.97 (m, 2H), 2.21 (s, 1H), 2.46 (t, 4H, J 5.0), 3.12 (t, 4H, J5.0), 3.96 (m, 1H), 6.96 (d, 1H, J 6.0), 7.39 (dd, 1H, J 9.0 &3.0), 8.00(d, 1H, J 9.0), 8.01 (d, 1H, J 3.0), 8.50 (d, 1H, J 5.5), 8.59 (d, 1H, J7.0), 9.62(s, 1H). HRMS (ESI): m/z 505.2103 [M+H]⁺; calcd. forC₂₃H₂₈F₃N₈S⁺ [M+H]⁺ 505:2104, Anal, RP-HPLC Method A: t_(R) 10.40 min,purity 96%; Method B: t_(R) 9.46 min, >97%:.

N-Cyclopentyl-5-(2-((5-(4-ethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine(66)

To a mixture of crude 1-5-(4-ethylpiperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (496 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 mg, 1.00 mmol) 2-methoxy ethanol (3 mL) was addedNaOH (80.0 mg, 2.00 mmol). The reaction mixture was heated at 180° C.under microwave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=96:4) andrecrystallised from MeOH to give 66 as a yellow solid (117 mg, 25%).1_(H) NMR (CDCl₃) δ 1.14 (t, 3H, 1.56-1.76 (m, 6H), 2.06-2.12 (m, 2H)2.49 (q, 2H, J 7.5), 2.54 (s, 3H), 2.4 (s,3H), 3.19 (t, 4H, J 4.5), 3.14(t,4H, J 5.0), 3.86 (app s, 1H), 5.77 (s, 1H), 6.84 (d, 1H, J 5.0), (dd,1H, J 9.0 & 3.0), 7.94 (d, 1H, J 3.0), 7.94 (s, 1H), 8.01 (d, 1H, J3.0), 8.26 (d, 1H, J 9.0), 8.33 (d, 1H, J 5.5). HRMS (ESI): m/z 465.2541[M+H]⁺; calcd. for C₂₄H₃₃N₈S⁺ [M+H]⁺ 455.2543. Anal. RP-HPLC Method A:t_(R) 13.24 min, purity >98%; Method B: t_(R) 8.96 min, purity 100%.

N-cyclopentyl-5-(2-((5-(4-ethylpiperazin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine(67)

To a mixture of crude 1-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (497 mg, 2.00 mmol) and((E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=95:5) to give 67 as a yellow solid (74 mg,15%). 1_(H) NMR (DMSO-d₆) δ 1.03 (t, 3H, J 7.0), 1.50-1.57 (m, 4H),1.66-1.69 (m, 2H), 1.90-1.95 (m, 2H), 2.37 (q, 2H, J 7.0), 2.46 (d, 3H,J 2.5), 3.11 (t, 4H, J 5.0), 3.32 (s, 4H), 3.96 (app s, 1H), 7.39 (dd,1H, J 9.0 & 3.0), 7.94 (d, 1H, J 9.0), 7.97 (d, 1H, J 3.0), 8.23 (d, 1H,J 7.0), 8.40 (d, 1H, J 3.5), 9.44 (s, 1H). HRMS (ESI): m/z 483.2442[M+H]⁺; calcd for C₂₄H₃₂FN₈S⁺ [M+H]⁺ 483.2449. Anal. RP-HPLC. Method A:t_(R) 9.78 min, purity >98%; Method B: t_(R) 7.88 min, purity 100%.

1-(4-(6-((4-(2-(Cyclopentylamino)-4-methylthiazol-5-yl) pyrimidin-2-yl)amino) pyridin-3-yl) piperazin-1-yl) ethan-1-one (68)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) wasadded NaOH (80.0 mg, 2 00 mmol). The reaction mixture was heated at 180°C. under microwave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified by usingchromatography (silica gel, DCM ramping to DCM:MeOH=90:10) to give 68 asa light yellow solid (153 mg, 32%). m.p. 207-210° C. 1_(H) NMR (CDCl₃) δ1.57-1.75 (m, 6H), 2.05-2.11 (m, 2H), 2.14 (s, 3H), 2.54 (s, 3H),3.08-3.14 (m, 4H), 3.63 (t, 2H, J 5.0), 3.79 (t, 2H, J 5.0), 3.87 (m,1H), 5.70 (s, 1H), 6.86 (d, 1H, J 5.0), 7.33 (dd, 1H, J 9.0 & 3.0), 8.03(d, 1H, J 2.0), 8.19 (br s, 1H,), 8.31 (d, 1H, J 9.0), 8.35 (d, 1H, J5.0). HRMS (ESI): m/z 479.2340 [M+H]⁺; calcd. for C₂₄H₃₁N₈OS⁺ [M+H]⁺479.2336 Anal. RP-HPLC Method A: t_(R) 10.86 min, purity >99%.; MethodB: t_(R) 8.51 min, purity >98%.

1-(4-(6-((4-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(69)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was addedNaOH (80.0 mg, 2.00 mmol). The reaction mixture was heated at 180° C.under microwave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified by usingchromatography (silica gel, DCM ramping to DCM:MeOH=90:10) to give 69 asa light yellow solid (153 mg, 32%). Yellow solid (53 mg, 11%). 1_(H) NMR(DMSO-d₆) δ 1.51-1.75 (m, 4H), 1.66-1.68 (m, 2H), 1.92-1.95 (m 2H), 2.04(s, 3H), 2.47 (d, 3H, J 2.0), 3.06 (t, 2H, J 5.0), 3.12 (t, 2H, J 5.0),3.58 (t, 4H, J 5.0), 3.96 (t, 1H), 7.43 (dd, 1H, J 9.0 & 3.0), 7,98 (d,1H, J 9.0) 8.01 (d, 1H, 3.0), 8.24 (d, 1H J 7.0), 8.42 (d, 1H, J 3.5),9.51 (br s, 1H). HRMS (ESI): m/z 497.2245 calcd. for C₂₄H₂₀FN₈OS⁺ [M+H]⁺407.2242 Anal. RP-HPLC Method A: t_(R) 11.02 min, purity >97%; Method B:t_(R) 9.91 min, purity >96%.

1-(4-(6-((4-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(70)

To a mixture of crude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(524 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5yl)-3-(dimethylamino)prop-2-en-1-one(333 mg, 1.00mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by using chromatography(silica gel, DCM ramping to DCM:MeOH=96:4) to give 70 as a brown solid(50 mg, 9%. 1_(H) NMR (DMSO-d₆) δ 1.53-1.59 (m, 4H), 1.67-1.69 (m, 2H,),1.94-1.97 (m, 2H), 2.05 (s, 3H), 3.08 (t, 2H, J 4.5), 3.59 (app 4H, J4.5), 3.95 (m, 1H), 6,97 (d, 1H, J 5.0), 7.43 (dd, 1H, J 9.0 & 3.0),8.02 (s, 1H), 8.04 (d, 1H, J 3.0) 8.50 (d, 1H, J 5.5), 8.59 (d, 1H, J6.5), 9.66 (s, 1H), HRMS (ESI): m/z 533.2053 [M+H]⁺; calcd. forC₂₄H₂₇F₃N₈OS⁺ [M+H]⁺ 533.2052. Anal. RP-HPLCMethod A: t_(R) 12.56 min,purity >97%; Method B: t_(R) 9.39 min, >95%.

N-cyclopentyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(71)

To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidinetrifluoroacetate (442 mg, 2.00 mmol ) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 1.00 mmol) 2-methoxy ethanol (3 mL) was added NaOH(80.0 mg, 2.00 mmol). The reaction mixture was heated at 180° C. undermicrowave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purifiedchromatography (silica gel, DCM ramping to DCM:MeOH=94:6) andrecrystallised with Et₂O to give 71 as a dark brown solid (130 mg, m.p.262-263° C.1_(H) NMR (CDCl₃) δ 1.57-1.74 (m, 6H), 2.06-2.12 (m, 2H),2.55 (s, 3H), (t, 4H, J 4.5), 3.88 (t, 4H, J 4.5), 5.67 (d, J 4.5, 1H),6.85 (d, 1H, J 5.5), 7.32 (dd, 1H, J 9.0 & 3.0), 8.02 (d, 1H, J 3.0),8.16 (s, 1H), 8.30 (d, 1H J 9.5), 8.35 (d, 1H, J 5.5). HRMS (ESI): m/z438.2088 [M+H]⁺; calcd. for C₂₂H₂₈N₇OS⁺ [M+H]⁺ 438.2071. Anal. RP-HPLC:Method A: t_(R) 10.92 min, purity 100%; Method B: t_(R) 9.51 min, purity>99%.

N-cyclopentyl-5-(2((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine(72)

To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidinetrifluoroacetate (442 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3(dimethylamino)-2-fluoroprop-2-en-1-one(297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol) The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=96:4) and recrystallised with DCM and MeOHto give 72 as a brown solid (120 mg, 26%). 1_(H) NMR (DMSO-d₆) δ1.50-1.57 (m, 4H), 1.66-1.69 (m, 2H), 1.90-1.95 (m, 2H), 2.47(d, 1H, J2.5), 3.09 (t, 4H, J 5.0), 3.75 (t, 4H, J 5.0), 3.96 (m, 1H), 7.42 (dd,1H, J 9.0 & 3.0), 7.96 (d, 1H, J 9.0), 7.98 (d, 1H, J 3.0), 8.24 (d, 1H,J 7.0), 8.41 (d, 1H, J 7.0), 9.52 (s, 1H). HRMS (ESI): m/z 456.1976[M+H]⁺; calcd. for C₂₂H₂₅F₃N₇OS⁺ [M+H]⁺ 456.1967 Anal. RP-HPLC Method A:t_(R) 11.28 min, purity 96%; Method B: t_(R) 8.93 min, 100%.

N-cyclopentyl-5-(2-((5-morpholinopyriidin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine(73)

To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidinetrifluoroacetate (442 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one(333 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 H, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, PE ramping to PE:EtOAc=60:40) to give 73 as an orange solid (200mg, 41%). 1_(H) NMR (DMSO-d₆) δ 1.52-1.59 (m, 4H), 1.64-1.69 (m, 2H),1.92-1.99 (m, 2H), 3.09 (t, 4H, J 4.5), 3.75 (t, 4H, J 4.5), 3.95 (m,1H), 6.97 (d, 1H, J 5.0), 7.41 (dd, 1H, J 9.0 & 3.0), 8.01 (s, 1H), 8.02(d, 1H, J 2.5), 8.51 (d, 1H, J 5.5), 8.59 (d, 1H, J 6.5), 9.64 (s, 1H).HRMS (ESI): m/z 492.1786 [M+H]⁺;calcd. for C₂₂H₂₄F₃N₇OS⁺ [M+H]⁺498.1788. Anal. RP-HPLC Method A: t_(R) 12.90 min, purity >97%; MethodB: t_(R) 9.69 min, >99%.

5-(2-((5-(4-Aminopiperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine(74)

To a mixture of crude 1-(5-(4-aminopiperidin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (702mg, 3.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (558 mg, 2.00 mmol) in 2-methoxy ethanol (5 mL) wasadded NaOH (160.0 mg, 4.00 mmol). The reaction mixture was heated at180° C. under microwave irradiation for 2 h, cooled to room temperatureand concentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH:MH₄OH=90:10:1) andrecrystallised with n-hexane and DCM to give 74 as a dark yellow solid(90 mg, 10%). m.p. 185-186° C. 1_(H) NMR (CDCl₃) δ 1.50-1.77 (m, 10H),1.95 (d, 2H, J 10.5), 2.07-2.13 (m, 2H), 2.54 (s, 3H), 2.75-2.85 (m,3H), 3.53-3.56 (m, 2H), 3.85-3.91 (m, 1H), 5.43 (d, J 5.0, 1H), 6.84 (d,1H, J 5.5), 7.34 (dd, 1H, J 9.0 & 3.0), 7.75 (s, 1H), 8.00 (d, 1H, J3.0). 8.25 (d, 1H, J 9.0), 8.32 (d, 1H, J 5.5). HRMS (ESI): m/z 451.2415[M+H]⁺; calcd. for C₂₃H₃₁N₈S⁺ [M+H]⁺ 451.2387. Anal. RP-HPLC Method A:t_(R) 9.34 min, purity >95%; Method B: t_(R) 8.06 min, purity >95%.

N-cyclopentyl-4-methyl-5-(2-((5-(piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(75)

To a mixture of crude 1-(5-(piperidin-1-yl)pyridin-2-yl)guanidine (439mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethyiamino)prop-2-en-1-one (279 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) wasadded NaOH (80.0 mg, 2.00 mmol). The reaction mixture was heated at 180°C. under microwave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=92:8) andrecrystallised with DCM and MeOH to give 75 as yellow solid (250 mg,57%). 1_(H) NMR (DMSO-d₆) δ 1.53 (s br, 6H), 1.64 (s br, 6H), 1.93 (sbr, 2H), 2.46 (s, 3H), 3.07 (t, 4H, J 10.0), 3.98 (s br, H), 6.89 (d,1H, J 5.0), 7.37 (app d, 1H, J 9.0), 7.99 (s, 1H), 8.06 (d, 1H, J 9.0),8.18 (s, 1H), 8.33 (d, 1H, J 5.0), 9.26 (s, 1H). HRMS (ESI): m/z436.2280 [M+H]⁺; calcd. for C₂₃H₃₀N₇S⁺ [M+H]⁺ 436.2278. Anal. RP-HPLCMethod A: t_(R) 12.08 min, purity >99%, Method B: t_(R) 9.36 min, >99%.

N-cyclopentyl-4-methyl-5-(2-(pyridin-2-ylamino)pyrimidin-4-yl)thiazol-2-amine(78)

To a mixture of crude 1-pyridin-2-yl)guanidine 2,2,2-trifluoroacetate(272 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (279 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) wasadded NaOH (80.0 mg, 2.00 mmol). The reaction mixture was healed at 180°C. under microwave irradiation for 1 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=97:3) to give 78 asan orange solid (150 mg, 43%). 1_(H) NMR (DMSO-d6) 1.50-1.57 (m, 4H),1.66-1.69 (m, 2H), 1.91-1.95 (m, 2H), 2.48 (s, 3H), 3.98 (m, 1H), 6.99(m, 2H), 7.74 (m, 1H), 8.23 (d, 1H, J 7.0). 8.26 (d, 1H, J 8.5), 8.29(m, 1H), 8.39 (d, 1H, J 5.5), 9.59 (s, 1H) HRMS (ESI): m/z 353.1555[M+H]⁺; calcd. for C₁₈H₃₁N₆S⁺ [M+H]⁺ 353.1543. Anal. RP-HPLC Method A:t_(R) 10.45 min, purity >97%; Method B: t_(R) 9.24 min, purity >98%.

4-(6-((4-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carbaldehyde(79)

Compound 79 was obtained as beige solid (25 mg, 7%) by-product in theprocess of synthesising and purifyingN-cyclopentyl-5-(2-((5-(piperazin-4-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine.1_(H) NMR (DMSO-d₆) 1.53-1.59 (m, 4H), 1.67-1.69 (m, 2H), 1.94-1.97 (m,2H), 3.08 (t, 2H, J 5.0), 3.14 (t, 2H, J 5.0), 3.59 (m, 4H), 3.96 (m,1H), 6.97 (d, 1H, J 4.5), 7.45 (dd, 1H, J 9.0 & 3.0), 8.03 (d, 1H, J9.0), 8.05 (d, 1H, J 3.0), 8.09 (s, 1H), 8.50 (d, 1H, J 5.5), 8.59 (d,1H, J 7.0), 9.67 (s, 1H). HRMS (ESI): m/z 519.1897 [M+H]⁺; calcd. forC₂₃H₂₆F₃N₈OS⁺ [M+H]⁺ 519,1906. Anal. RP-HPLC Method A: t_(r) 11.57 min,purity >91%: Method B: t_(R) 9.39 min, >95%.

N-cyclopentyl-5(-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine(80)

To a mixture of crude1-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (524 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH NH₄OH=90:10:1) to give 80 as yellow solid(134 mg, 27%). 1_(H) NMR (DMSO-d₆) δ 1.49-1.56 (m, 6H), 1.64-1.70 (m,2H), 1.84 (d, 3H, J 1.5), 1.90-1.96 (m, 2H), 2.20 (s, 7H), 2.46 (s, 3H),2.65 (t, 2H, J 11.0), 3.63 (d, 1H, J 12.0), 3.92-3.99 (m, 1H), 7.39 (dd,1H, J 9.0 & 3.0), 7.93 (d, 1H, J 9.0), 7.98 (d, 1H, J 2.5), 8.23( 1H, J7.0), 8.40 (d, 1H, J 3.0), 9.41 (s, 1H). HRMS (ESI): m/z 497.2608[M+H]⁺; calcd. for C₂₅H₃₄FN₈S⁺ [M+H]⁺ 497.2606. Anal. RP-HPLC Method A:t_(R) 9.81 min, purity >95%; Method B: t_(R) 8.75 min, >99%.

5-(2-((5-(1,4-diazepan-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine(81)

To a mixture of crude 1-(5-(1,4-diazepan-1-yl)pyridin-2-yl)guanidinedi(2,2,2-trifluoroacetate) (469 mg, 2.00 mmol) and(E)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=90:10) to give 81 as a yellow solid (100mg, 21%). 1_(H) NMR (DMSO-d₆) 1.49-1.59 (m, 4H), 1.64-1.72 (m, 2H),1.92-1.95 (m, 2H), 2.05-2.09 (m, 2H), 2.47 (d, 3H, J 2.0), 2.55 (s, 1H),3.16 (s br, 2H), 3.27 (d, 2H, J 4.0), 3.70 (t, 2H, J 5.0), 3.94-3.98 (m,1H), 7.32 (dd, 1H, J 9.0 & 3.0), 7.87 (d, 1H, J 2.5), 7.89 (d, 1H, J3.0), 8.27 (d, 1H, J 7.0), 8.40 (d, 1H, J 3.5), 8.9 (s br, 1H), 9.54 (s,1H). HRMS (ESI): m/z 469.2297 [M+H]⁺; calcd. for C₂₃H₃₀FN₈S⁺ [M+H]⁺469.2293. Anal. RP-HPLC Method A: t_(R) 9.53 min, purity >97%; Method B:t_(R) 8.53 min, 100%.

N-cyclopentyl-5-(5-fluoro-2-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine(82)

To a mixture of crude1-(5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)guanidine (596 mg,2.00 mmol) and(E)-1-(2-cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one(297 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=96:4) to give 82 as yellow solid (53 mg,10%), 1_(H) NMR (DMSO-d₆) 1.51-1.57 (m, 4H), 1.66-1.68 (m, 2H),1.91-1,95 (m, 2H), 2.47 (s, 3H), 2.94 (s, 3H), 3.22 (t, 4H, J 5.0), 3.26(t, 4H, J 5.0), 3.95-3.97 (m, 1H), 7.46 (dd, 1H, J 9.0 & 2.5), 7.98 (d,1H, J 9.0), 8,02 (d, 1H, J 2.5), 8.24 (d, 1H, J 7.0), 8.42 (d, 1H, J3.5), 9.57 (s, 1H). HRMS (ESI): m/z 533.1916 [M+H]⁺; calcd. forC₂₃H₃₀FN₈O₂S₂ ⁺ [M+H]⁺ 533.1912. Anal. RP-HPLC Method A: t_(R)10.96 min,purity >99%; Method B: t_(R) 10.25 min, purity >98%.

N-cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine(83)

To a solution of5-(2-aminopyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine (275 mg,1.00 mmol) in dioxane (3 mL) were added1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperizine (341 mg, 1.2 mmol).Pd₂dba₃ (45.8 mg, 0.05 mmol), xantphose (58 mg, 0.1 mmol) and t-BuONa(144 mg, 1.5 mmol) and heated under microwave irradiation at 150° C. for1 h. The reaction mixture was cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH:NH₄OH=9:1:0.3) andrecrystallised with DCM and MeOH to give 83 as a white solid (200 mg,42%). 1_(H) NMR (CDCl₃) δ 1.09 (t, 3H, J 7.0), 1.58-1.76 (m, 6H),2.08-2.14 (m, 2H), 2.43 (q, 2H, J 7.0, CH₂CH₃), 2.55 (s br, 11H), 3.48(s, 2H), 3.86-3.92 (m, 1H), 5.42 (d, 2H, J 7.0), 6.90(d, 1H, J 5.5),7.68 (dd, 2H, J 9.0 & 2.5), 7.89 (s, 1H), 8.19 (d, 1H, J 2.0), 8.35-8.38(m, 2H). HRMS (ESI): m/z 479.2703[M+H]⁺; calcd. for C₂₅H₃₅N₈S⁺[M+H]⁺479.2700. Anal. RP-HPLC Method A: t_(R) 9.89 min, purity >96%:Method B: t_(R) 8.66 min. purity >96%.

N-cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine(84)

To a solution of5-(2-amino-5-fluoropyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine(200 mg, 0.68 mmol) in dioxane (3 mL) were added1-(6-bromopyridin-3-yl)methyl)-4-ethylpiperazine(233. mg, 0.82 mmol),Pd2dba3(31 mg, 0.034 mmol), xantphose (41 mg, 0.07 mmol) and t-BuONa (98mg, 1.02 mmol) and heated under microwave irradiation at 150° C. for 1h. The reaction mixture was cooled to room temperature and concentratedunder reduced pressure. The residue was purified by chromatography(silica gel, DCM tamping to DCM:MeOH=93.7) to give 84 as an orange solid(100 mg, 29%). 1_(H) NMR (DMSO-d₆) δ 0.09 (t, 3H, J 7.0), 1.49-1.59 (m,4H), 1.64-1.72 (m, 2H), 1.90-1.97 (m, 2H), 2.38 (s br, 10H), 2.48 (d,3H, J 2.5), 3.42 (s, 2H), 3.95-3.98 (m, 1H), 7.64 (dd, 1H 8.5 & 2 0),8.10 (d, 1H, J 8.5), 8.16 (d, 1H, J 2.0), 8.27 (d, 1H, J 7.0), 8.46 (d,1H, J 3.5), 9.77 (s, 1H). HRMS (ESI): m/z 497.2601 [M+H]⁺; calcd. forC₂₅H₃₄FN₈S⁺ [M+H]⁺ 497.2606. Anal. RP-HPLC Method A: t_(R) 9.89 min,purity >96%; Method B: t_(R) 8.66 min, purity >96%.

N-Cyclopentyl-N,4-dimethyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(85)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (319 mg, 1.45 mmol) and(E)-1-(2-(cyclopentylmethyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one(250 mg, 0.85 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (68.0 mg,1.70 mmol) The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=93:7) and recrystallised with hexane togive 85 as a reddish brown solid (113 mg, 25%). m.p. 166-169° C. 1_(H)NMR (CDCl3) δ 1.58-1.79 (m, 6H), 1.96-2.02 (m, 2H), 2.11 (br, 1H). 2.56(s, 3H), 3.01 (s, 3H). 3 06 (t, 4H, J 6 ), 3.10 (t, 4H, J 6.0), 4.55 (m,1H), 6.82 (d, 1H, J 5.5), 7.32 (dd, 1H, J 9.0 & 3.0), 8.02 (d, 1H, J3.0), 8.13 (br, 1H), 8.28 (d, 1H, J 9.0), 8.32 (d, 1H, J 5.5). HRMS(ESI): m/z 451.2387 [M+H]⁺; calcd. C₂₃H₃₁N₈S⁺[M+H]⁺ 451.2387. Anal.RP-HPLC Method A: t_(R) 10.28 min, purity>95%; Method B: t_(R) 8.69 min,purity>95%.

N-Cyclopentyl-N,4-dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(86)

To a mixture of crude 1-(5-(4-methyipiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate (468 mg, 2.00 mmol) and(E)-1-(2-(cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one(293 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h. cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM MeOH:NH₄OH=93:7:0.5) and recrystallised withMeOH to give 86 as a yellow solid (149 mg, 32%), m.p. 169-170° C. 1_(H)NMR (CDCl₃) δ 1.65-1.76 (m, 6H), 1.99-2.02 (m, 2H), 2.56 (s, 3H), 2.75(s, 3H), 2.75 (s, 3H), 3.16 (br, 4H), 3.47 (t, 4H, J 5.0), 4.58 (m, 1H),6.86 (d, 1H, J 5.5), 7.36 (dd, 1H, J 9.0 & 3.0), 8.05 (d, 1H, J 3.0),8.07 (s, 1H), 8.32 (d, 1H, J 5.5), 8.35 (d, 1H, J 9.0). HRMS (ESI): m/z465.2530 [M+H]⁺; calcd. for C₂₄H₃₃N₈S⁺ [M+H]⁺ 465.2543 Anal. RP-HPLCMethod A: t_(R) 10.15 min. purity>96%; Method B: t_(R) 8.47 min.purity>96%.

1-(4-(6-((4-(2-(Cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one(87)

To a mixture of etude1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate(525 mg, 2.00 mmol) and(E)-1-(2-(cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one(293 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silica getDCM ramping 10 DCM:MeOH=96:4) and recrystallised with Et₂O to give 87 asa yellow solid (300 mg, 61%). m.p. 153-154° C. 1_(H) NMR (CDCl₃) δ1.61-1.76 (m, 6H), 1.97-2.02 (m, 2H), 2.15 (s, 3H), 2.57 (s, 3H), 3.01(s, 3H), 3.09 (t, 2H, J 5.0), 3.13 (t, 2H, J 5.0), 3.63 (t, 2H, J 5.0),3.79 (t, 2H, J 5.0), 4.56 (m, 1H), 6.85 (d, 1H, J 5.5), 7.34 (dd, 1H, J9.0 & 3.0), 7.93 (s, 1H), 8.00 (d, 1H, J 3.0), 8.31 (s, 1H), 8.32 (d,1H, J 5.0). HRMS (ESI): m/z 493.2482 [M+H]⁺; calcd. for C₂₅H₃₃N₈OS⁺[M+H]⁺ 493.2493. Anal. RP-HPLC Method A: t_(R) 11.55 min, purity>96%;Method B: t_(R) 9.57 min. purity>96%.

N,N-Dicyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(88)

To a mixture of crude 1-(5-(piperazin)-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (441 mg, 2.00 mmol) and(E)-1-(2-(Dicyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (218) mg, 0.58 mmol) in 2-methoxy ethanol (3 mL) wasadded NaOH (80.0 mg, 2,00 mmol). The reaction mixture was heated at 180°C. under microwave irradiation for 2 h, cooled to room temperature andconcentrated under reduced pressure. The residue was purified bychromatography (silica gel, DCM ramping to DCM:MeOH=90:10) andrecrystallised with DCM and McOH to give 88 yellow solid (60 mg, 21%).1_(H) NMR(CDCl₃) 1.53-1.59 (m, 8H), 1.74-1.76 (m, 4H), 1.85-1.89 (m,2H), 1.91-1.98 (m, 2H), 2.42-2.47 (m, 1H), 2.58 (s, 3H), 3.05 (t, 4H, J3.0), 3.10 (t, 4H, J 3.0), 3.41-3.44 (m, 1H), 4.47-4.54 (m, 1H), 6.61(d, 1H, J 5.5), 7.32 (dd, 1H, J 9.0 & 3.0), 7.70 (s, 1H), 7.98 (d, 1H, J3.0), 8.25 (d, 1H, J 9.0), 8.28 (d, 1H, J 5.5). HRMS (ESI) m/z 505.2873[M+H]⁺; calcd. for C₂₇H₃₇N₈S⁺ [M+H]⁺ 505.2856. Anal. RP-HPLC Method A:t_(R) 8.57 min, purity >98%; Method B: t_(R) 7.33 min, purity >96%,

4-Methyl-N-phenyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine(89)

To a mixture of crude 1-(5-(piperazin-1-yl)pyridin-2-yl)guanidinetrifluoroacetate (468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(4-methyl-2-(phenylamino)thiazol-5-yl)prop-2-en-1-one(287 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure The residue was purified by chromatography (silica gel,DCM ramping to DCM:MeOH:NH₄OH=90:10:0.5) to give 89 as a light yellowsolid (178 mg, 40%). m.p. 228-230° C. 1_(H) NMR (DMSO-d₆) δ 2.58 (s,4H), 2.86 (t, 4H, J 4.5), 3.03 (t, 4H, J 4), 7.00 (m, 2H), 7.35 (m, 3H),7.65 (d, 2H, J 8.0), 8.00(d, 1H, J 2.5), 8.06 (d, 1H, J 9.0), 8.41 (d,1H, J 5.0), 9.46 (s, 1H), 10.53 (s, 1H). HRMS (ESI): m/z 445.1918[M+H]⁺; calcd for C₂₃H₂₅N₈S⁺ [M+H]⁺ 445.1917 Anal. RP-HPLC Method A:t_(R) 10.01 min. purity 100%; Method B: t_(R) 8.17 min, purity 100%.

4-Methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-phenylthiazol-2-amine(90)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(4-mehtyl-2-(phenylamino)thiazol-5-yl)prop-2-en-1-one(287 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2 00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 hr, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=90:8) and recrystallised with DCM to give90 as a light yellow (220 mg, 48%). m.p. 210-211° C. 1_(H) NMR (DMSO-d₆)δ 2.23 (s, 3H), 2.58 (s, 3H), 3.12 (br, 4H), 3.38 (t, 4H), 7.00 (m, 2H),7.37 (m, 3H), 7.65 (d, 2H, J 8.0), 8.01 (d, 1H, J 2.0), 8.07 (d, 1H, J9.0), 8.41 (d, 1H, J 5.0). 9.46 (s, 1H), 10.54 (s, 1H). HRMS (ESI): m/z459.2063 [M+H]⁺; calcd. for C₂₄H₂₇N₈S⁺ [M+H]⁺ 459.2074. Anal. RP-HPLCMethod A: t_(R) 9.93 min, purity 100%, Method B: t_(R) 9.17 min, purity100%.

N,4-Dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-phenylthiazol-2-amine(91)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-3-(dimethylamino)-1-(4-methyl-2-(methyl(phenyl)amino)thiazol-5-yl)prop-2-en-1-one(301 mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg,2.00 mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=92:8) and recrystallised with hexane togive 91 as a reddish brown solid (184 mg, 39%). m.p. 212-215° C. 1_(H)NMR (CDCl₃) δ 2.36 (s, 3H), 2.59 (app br, 7H), 3.14 (t, 4H, J 5.0), 3.57(s, 3H), 6.80 (d, 1H, J 5.5), 7.19 (dd, 1H, J 9.0 & 3.0), 7.32 (m, 1H),7.44 (m, 4H), 8.00 (d, 1H, J 3.0), 8.04 (s, 1H), 8.16 (d, 1H, J 9.0),8.32 (d, 1H, J 5.5). HRMS (ESI): m/z 473.2220 [M+H]⁺; calcd. forC₂₅H₂₉N₈S⁺ [M+H]⁺ 473.2230. Anal. RP-HPLC Method A: t_(R) 9.57 min,purity >98%; Method B: t_(R) 7.90 min, purity >98%.

4-Methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one(92)

Compound 92 was obtained as a grey solid (31 mg, 10%) by-product in theprocess of synthesising and purifying4-(2-Methoxy-4-methylthiazol-5-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine.m.p. 228-230° C. 1_(H) NMR (DMSO-d₆) 2.23 (s, 3H), 2.42 (s, 3H), 2.47(t, 4H, J 4.5), 3.12 (t, 4H, J 4.5), 6.90 (d, 1H, J 5.0), 7.45 (dd, 1H,J 9.0 & 3.0), 7.99 (d, 1H, J 3.0), 8.02 (d, 1H, J 9.0), 8.41 (d, 1H, J5.0), 9.53 (s, 1H). HRMS (ESI): m/z 384.1596 [M+H]⁺;calcd. forC₁₈H₂₂N₇OS⁺ [M+H]⁺ 384.1601. Anal. RP-HPLC Method A: t_(R) 8.59 min,purity >97%; Method B: t_(R) 3.59 min. purity >99%

3,4-Dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one(93)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-5-(3-(dimethylamino)acryloyl)-3,4-dimethylthiazol-2(3H)-one (226 mg,1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was healed at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM MeOH:NH₄OH 94:6:05) and recrystallised withhexane to give 93 as a yellow solid (72 mg, 18%). m.p 243-244° C. 1_(H)NMR (CDCl₃) 2.37 (s, 3H), 2.59 (s, 3H), 2.61 (t, 4H, J 4.0), 3.19 (t,4H, J 4.0). 3.37 (s, 3H), 6.73 (d, 1H, J 5.0), 7.34 (dd, 1H, J 9.0 &3.0), 7.87 (s, 1H), 8.00 (d, 1H, J 3.0), 8.21 (d, 1H, J 9.0), 8.406 (d,1H, J 5.0). HRMS (ESI): m/z 398.1769 [M+H]⁺; calcd for C₁₉H₂₄N₇OS⁺[M+H]⁺ 398.1758. Anal. RP-HPLC Method A: t_(R) 8.25 min, purity 100%;Method B: t_(R) 3.31 min, purity 100%.

3-Ethyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one(94)

To a mixture of crude1-(5-(4-methylpiperazin-1-yl)pyridine-2-yl)guanidine trifluoroacetate(468 mg, 2.00 mmol) and(E)-5-(3-(dimethylamino)acryloyl)-3-ethyl-4-methylthiazol-2(3H)-one (240mg, 1.00 mmol) in 2-methoxy ethanol (3 mL) was added NaOH (80.0 mg, 2.00mmol). The reaction mixture was heated at 180° C. under microwaveirradiation for 1 h, cooled to room temperature and concentrated underreduced pressure. The residue was purified by chromatography (silicagel, DCM ramping to DCM:MeOH=94:6) to give 94 as a yellow solid (108 mg,26%). m.p. 181-182° C. 1_(H) NMR (CDCl₃) 1.31 (t, 3H, J 7.0), 2.37 (s,3H), 2.59 (s, 3H), 2.61 (t, 4H, J 5.0), 3.19 (t, 4H, H 5.0), 3.87 (q,3H, J 7.0), 6.73 (d, 1H, J 5.0), 7.34 (dd, 1H, J 9.0 & 3.0), 8.03 (s,1H), 8.22 (s, 1H), 8.22 (d, 1H, J 9.0), 8.40 (d, 1H, J 5.0). HRMS (ESI):m/z 412.1888 [M+H]⁺; calcd. for C₂₀H₂₆N₇OS⁺ [M+H]⁺ 412.1914. Anal.RP-HPLC Method A: t_(R) 8.36 min, purity >99%; Method B: t_(R) 3.23 min,purity >95%.

5-(2-((5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2(3H)-one(95)

Compound 95 was obtained as a brown solid (30 mg, 7%) by-product in theprocess of synthesising and purifying1-(4-(6-((4-(4-methyl-2-(methylthio)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one.1_(H) NMR (DMSO-d₆) 2.04 (s, 3H), 2.42 (s, 3H), 3.07 (t, 2H, J 5.0),3.14 (t, 2H, J 5.0), 3.58 (app m, 4H), 6.91 (d, 1H, J 5.5), 7.50 (dd,1H, J 9.0 & 3.0), 8.02 (d, 1H, J 3.0), 8.05 (d, 1H, J 9.0), 8.42 (d, 1H,J 5.0), 9.56 (s, 1H). HRMS (ESI): m/z 412.1560 [M+H]⁺; calcd. forC₁₉H₂₂N₇O₂S⁺ [M+H]⁺; 412.1550. Anal. RP-HPLC Method A: t_(R) 9.03 mm.purity >99%; Method B: t_(R) 7.58 min, purity 100%.

3-Cyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one(96)

To a suspension of5-(2-((5-(4-acetylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-3-cyclopentyl-4-methylthiazol-2(3H)-one(100 mg. 0.21 mmol) in methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified byFlashMaster Personal® chromatography (silica gel, DCM ramping toDCM:MeOM)=9:1) to give 96 as a yellow solid (73 mg, 80%). 1_(H) NMR(CDCl₃) δ 1.61-1.64 (m, 2H), 1.90-1.99 (m, 4H), 2.26-2.30 (m, 2H), 2.58(s, 3H), 3.07 (t, 4H, J 2.5), 3.11 (t, 4H, J 3.0), 4.43 (m, 1H), 6.70(d, 1H, J 5.5), 7.34 (dd, 1H, J 9.0 & 3.0), 7.90 (s, 1H), 8.00 (d, 1H, J3.0), 8.22 (d, 1H, J 9.0), 8.39 (d, 1H, J 5.5). HRMS (ESI): m/z 438.2073[M+H]⁺; calcd. for C₂₂H₂₈N₇OS⁺ [M+H]⁺ 438.2071 Anal. RP-HPLC Method A:t_(R) 13.52 min, purity >94%, Method B: t_(R) 10.0 min. purity >99%.

4-Methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2(3H)-one(97)

To a suspension of5-(2-((5-(4-acetylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2(3H)-one(50 mg, 0.13 mmol) in methanol HCl (32%, 3 mL) was added and reflexedovernight. The reaction mixture was concentrated and purified byFlashMaster Personal® chromatography (silica gel, DCM ramping toDCM:MeOH NH₄OH)=9:1:1) to give 97 as a grey solid (41 mg, 91%). 1_(H)NMR (DMSO-d₆) 2.42 (s, 3H), 3.00 (t, 4H, J 5.0), 3.16 (t, 4H, J 5.0),6.91 (d, 1H, J 5.5), 7.47 (dd, 1H, J 9.0 & 3.0), 8.01 (d, 1H, J 3.0),8,04 (d, 1H, J 9.0), 8.41 (d, 1H, J 5.5), 9.54 (s, 1H). HRMS (ESI): m/z370.1433 [M+H]⁺; calcd. for C₁₇H₂₀N₇OS⁺ [M+H]⁺ 370.1445. Anal. RP-HPLCMethod A: t_(R) 7.42 mm. purity>97%; Method B: 3.59 min, purity>99%.

Example 2 Biological Activity Kinase Assays

Eurofins Pharma Discovery or Reaction Biology Corporation KinaseProfiler services were used to measure inhibition of CDKs and otherkinases by radiometric assay. Inhibition of CDK4/D1, CDK6/D3 and CDK9/T1were also determined in-house using ADP Glo Kinase assays (PromegaCorporation, Madison, USA). Briefly, the kinase reaction for CDK4/D1 andCDK6/D3 was performed with kinase reaction buffer (40 nM Tris base pH7.5, 20 mM MgCl2, 0.4 mM DTT), 0.1 mg/ml BSA and RB-CTF substrate(retinoblastoma protein1 C-terminal fraction). For CDK9/CyclinT1, thekinase reaction was performed with standard assay buffer and KinaseDilution Buffer and RBER-IRSride substrate. Serial dilutions of 1:3 wereprepared for test compounds for 10 concentrations (from 10 μM to 0.5nM). The kmasc reactions were started by addition of ATP incubated for40 min at 37° C. and then stopped by adding 10 μL of ADP Glo reagent.After incubation at room temperature in the dark for 40 min, 20 μL ofkinase detection reagent was added per well and incubated for 40 min.Luminescence was measured using an EnVision Multilabel plate reader(PerkinElmer, Buckinghamshire, UK). Positive and negative controls wereperformed in the presence and absence of CDK kinases, respectively.Half-maximal inhibition (IC₅₀) values were calculated using a4-parameter logistic non-linear regression model with Graphpad prism(Version 6.0). Apparent inhibition constants (K_(i)) values werecalculated from K_(m) (ATP) and IC₅₀ values for the respective kinases.The results are shown in Table 2.

Cell Viability Assay

Compounds from Example 1 were subjected to a standard MTT(3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide) andresazurin assays on solid tumour cell lines and leukemia cell lines,respectively, as previously reported (Wang S et al., J Med Chem47:1662-1675. 2004 and Diab S. et al. CheMedChem 9:962-972, 2014).Compound concentrations required to inhibit 50% of cell growth (GI₅₀)were calculated using non-linear regression analysis. The results areshown in Tables 3 and 4

Cell Cycle Analysis and Apoptosis

Cell cycle analysis and apoptosis studies were performed as describedpreviously (Diab S. et al. CheMedChem 9:962-972, 2014; Teo T., et al.Cancer Letters, 357(2):612-623, 2015). Briefly, human acute myeloidleukaemia MV4-11 cells (1×10⁵) were seeded and incubated overnight at37° C. and 5% CO₂. Ceils were centrifugal at 300×g for 5 min upontreatment with inhibitor. Cell pellets were collected and fixed with 70%ethanol on ice for 15 min, followed by centrifugation at 300×g for 5min. The collected pellets were incubated with staining solution (50μg/mL PI, 0.1 mg/mL ribonuclease A, 0.05% Triton X-100) at 37° C. for anhour and analysed with Gallios flow cytometer. 1×10⁵ of the remainingcells were then used in an apoptotic assay with Annexin V-FITC ApoptosisDetection Kit. The samples were analysed by FACS within one hour ofstaining. Data were analysed using Kaluza v1.2.

In an example shown in FIG. 1, MV4-11 cells were treated with compound60 for 24 h at the concentrations shown. It was found that compound 60arrested cells in the G1 phase of the cell-cycle in a dose-dependentmanner, confirming its inhibitory activity against cellular CDK4/6.Treatment of cancer cells with compounds resulted in apoptosis asrepresented by the sum of early (annexin-V+/PI−) and late(annexin-V+/PI+) apoptosis. A representative example is shown in FIG. 2.

Example 3 Pharmacokinetics

For pharmacokinetic measurements, healthy male adult Balb/C mice(weighing 20-25 g) or Wistar Rat (weighing 250-350 g) were split intoweight matched groups of 3 per group. Compound was administered IV (2mg/kg for mice, 5 mg/kg tor rats) via the tail vein or by oral gavage(20 mg/kg) Blood samples were collected from animals by jugular veincannula (rats) or under anaesthesia by cardiac puncture (mice) at timezero and at intervals up to 24 h. Harvested blood was centrifuged at7000×G for 2 minutes, and the plasma aspirated and frozen at −20° C.until analysts. Quantitative analysis of compound in plasma was tamedout using LC-MS/MS methods. Pharmacokinetic data derived using PhoenixWinNonlin 6.4® non-compartmental analysis. Oral bioavailability (% F)was calculated by taking the ratio of dose-normalised AUC values fromoral versus parenteral (IV) dosing Pharmacokinetic profiles of examplecompounds are shown in Table 5.

TABLE 2 Inhibition of cyclin-dependant kinases CDK inhibition K_(i) (μM)or % remaining enzymatic activity at 10 μM Compound CDK1B CDK 2A CDK4D1CDK6D3 CDK7H CDK9T1 1 >5 >5 0.081 0.590 >5 >5 2 >5 >5 0.055 0.245 >5 >55 >5 1.935 0.030 0.170 >5 >5 4 >5 >5 0.031 0.117 >5 2.037 5 >5 >5 0.0700.027 >5 >5 6 >5 >5 0.119 0.201 >5 >5 7 >5 1.71 0.059 0.237 >5 >5 8 >51.82 0.024 0.980 >5 >5 9 >5 1.80 0.010 1.670 >5 >5 10 >5 >5 0.290 ND* >5 >5 11 >5 >5 0.250 ND >5 >5 12 >5 2.34 0.180 ND >5 >5 13 3.7400.241 0.011 0.030 >5 >5 14 3.410 0.287 0.010 0.029 >5 4.180 15 3.0950.465 0.005 0.025 >5 >5 16 4.850 0.246 0.062 0.209 >5 >5 17 1.440 0.0600.001 0.004 4.690 1.725 18 >5 0.775 0.028 0.394 >5 >10 19 >5 3.645 0.3100.935 >5 4.764 20 >5 0.720 0.005 0.020 >5 4.530 21 >5 2.700 0.0070.042 >5 >5 22 >5 4.760 0.190 1.955 86% 80% 23 >5 0.180 0.0300.200 >5 >5 24 3.990 0.180 0.001 0.015 >5 4.610 25 >5 0.075 0.0050.020 >5 >5 26 >5 0.889 0.006 0.114 >5 2.850 27 56% 34% 0.001 0.040 39%11% 28 1.360 0.236 0.004 0.032 >5 0.784 29 3.205 0.650 0.005 0.050 >51.820 30 66% 36% 0.004 0.032 43%  9% 31 >5 0.365 0.002 0.010 >5 1.90532 >5 0.665 0.005 0.020 >5 2.925 33 3.101 0.310 0.578 3.032 >5 >5 34 >54.466 0.004 0.030 >5 >5 35 1.820 0.178 0.017 0.046 >5 4.070 36 >5 0.4590.020 0.610 >5 >5 37 >5 0.201 0.004 0.064 >5 >5 38 3.315 0.100 0.0050.030 >5 >5 39 >5 >5 0.169 2.710 >5 >5 40 >5 >5 0.016 0.036 >5 0.999 410.133 0.037 0.006 0.225 0.067 0.117 42 0.089 0.017 0.001 0.036 0.1010.034 43 >5 0.903 0.021 0.056 >5 >5 44 >5 0.335 0.004 0.040 >5 >5 45 >51.430 0.030 0.154 >5 >5 46 >5 1.39 0.002 0.055 >5 4.36 47 >5 3.335 0.0020.279 >5 >5 48 >5 0.976 0.087 0.234 >5 >5 49 >5 1.04 0.024 0.366 >5 >550 >5 0.069 0.044 ND >5 >5 51 ND ND >5 ND ND ND 52 0.580 0.076 0.0370.297 >5 >5 53 2.370 0.206 0.003 0.032 >5 3.037 54 ND ND >5 ND ND ND 553.140 0.240 0.005 0.011 0.775 2.420 56 3.815 0.399 0.003 0.015 0.7600.773 57 2.695 0.200 0.021 0.105 4.385 3.717 58 >5 0.127 0.0410.082 >5 >5 59 >5 0.800 0.016 0.028 1.160 0.925 60 >5 >5 0.001 0.0341.108 0.220 61 2.235 0.256 0.003 0.007 0.790 0.787 62 0.220 0.022 0.0080.002 0.194 0.258 63 2.675 0.206 0.002 0.009 0.865 0.180 64 2.330 0.1030.001 0.003 2.020 0.505 65 0.241 0.022 0.001 0.003 0.189 0.831 66 3.020.355 0.002 0.011 0.780 0.141 67 >5 0.349 0.002 0.006 0.685 >5 68 3.2520.776 0.006 0.093 3.453 0.286 69 >5 0.228 0.034 0.023 >5 4.990 70 0.2970.014 0.004 0.006 2.615 >5 71 >5 2.940 0.005 0.029 >5 >5 72 4.350 0.1040.006 0.020 >5 >5 73 >5 0.154 0.008 0.011 >5 >5 74 1.230 0.181 0.0030.133 1.187 0.173 75 >5 >5 0.070 0.257 >5 >5 76 4.070 0.278 0.001 0.0080.282 0.508 77 1.100 0.077 0.007 0.055 2.640 1.321 78 — — 0.570 — — >579 0.345 0.015 0.011 0.007 1.900 >5 80 >5 1.150 0.001 0.031 >5 1.09181 >5 0.417 0.014 0.010 0.815 0.679 82 >5 0.348 0.039 0.101 >5 >5 83 >50.416 0.006 0.009 0.211 1.984 84 >5 0.620 0.003 0.014 0.630 3.570 851.390 0.174 0.002 0.010 3.20 1.801 86 >5 0.476 0.002 0.010 >5 1.800 873.170 0.121 0.010 0.031 >5 >5 88 >15 >5 0.071 0.539 >5 >5 89 2.040 >50.005 0.066 1.660 0.436 90 >5 >5 0.019 0.485 >5 >5 91 >5 1.040 0.0260.100 >5 2.00 92 51% 61% 0.027 0.155 24% 0.950 93 71% 77% 0.255 0.91552% 0.840 94 3.660 1.340 0.033 0.320 1.260 1.580 95 55% 40% ND 25% 68%17% 96 63% 61% ND 11% 22% 15% 97 58% 54% ND 12% 24%  3%

TABLE 3 Anti-proliferative activity (72 h, GI₅₀ μM) of example compoundsCompound No. MV4-11 MDA-MB-453 1 1.099 ± 0.345 >10 2 1.021 ± 0.007 >10 30.053 ± 0.003 0.378 ± 0.029 4 0.296 ± 0.287 1.973 ± 0.404 5 0.500 ±0.247 0.914 ± 0.098 6 2.129 ± 0.969 >10 7 0.606 ± 0.150 3.860 ± 0.220 80.750 ± 0.246 3.009 ± 0.705 9 0.591 ± 0.083 3.320 ± 0.576 10 5.372 ±1.685 >10 11 >10 >10 12 5.294 ± 0.811 >10 13 0.029 ± 0.019 0.703 ± 0.07114 0.596 ± 0.231 >10 15 0.063 ± 0.026 0.542 ± 0.065 16 0.457 ± 0.122 >1017 0.649 ± 0.024 1.054 ± 0.203 18 0.418 ± 0.023 0.166 ± 0.117 19 3.518 ±1.044 >10 20 0.671 ± 0.091 3.137 ± 0.173 21 0.456 ± 0.066 7.156 ± 0.88622 2.511 ± 0.432 >10 23 0.073 ± 0.025 0.461 ± 0.059 24 0.066 ± 0.0194.877 ± 0.214 25 0.537 ± 0.117 0.514 ± 0.050 26 0.259 ± 0.241 — 27 0.014± 0.006 — 28 0.012 ± 0.003 0.248 ± 0.044 29 0.297 ± 0.061 0.544 ± 0.07830 0.056 ± 0.004 — 31 0.011 ± 0.004 0.381 ± 0.096 32 0.065 ± 0.002 0.528± 0.046 33 0.154 ± 0.074 5.840 ± 0.279 34 0.174 ± 0.022 0.813 ± 0.022 350.035 ± 0.004 4.912 ± 0.432 36 0.643 ± 0.018 — 37 0.465 ± 0.129 — 380.069 ± 0.005 5.407 ± 0.801 39 45.90 ± 2.520 — 40 0.084 ± 0.008 — 410.038 ± 0.006 — 42 0.037 ± 0.006 — 43 0.011 ± 0.021 0.894 ± 0.091 440.048 ± 0.004 0.237 ± 0.044 45 0.092 ± 0.004 2.102 ± 0.787 46 0.073 ±0.010 0.638 ± 0.042 47 0.107 ± 0.022 0.349 ± 0.036 48 0.537 ± 0.1334.718 ± 0.715 49 0.208 ± 0.030 2.369 ± 0.026 50 4.675 ± 0.298 5.358 ±0.501 51 0.606 ± 0.038 0.463 ± 0.075 52 0.425 ± 0.073 0.660 ± 0.092 530.080 ± 0.013 0.362 ± 0.003 54 2.158 ± 0.431 2.941 ± 0.507 55 0.093 ±0.010 0.031 ± 0.002 56 0.075 ± 0.005 0.618 ± 0.193 57 2.071 ± 0.3210.344 ± 0.126 58 0.032 ± 0.003 0.115 ± 0.024 59 0.255 ± 0.085 0.938 ±0.068 60 0.023 ± 0.024 0.070 ± 0.013 61 0.053 ± 0.004 0.780 ± 0.598 620.002 ± 0.001 0.081 ± 0.039 63 0.009 ± 0.000 0.130 ± 0.011 64 0.073 ±0.028 0.202 ± 0.030 65 0.001 ± 0.001 0.420 ± 0.120 66 0.009 ± 0.0010.287 ± 0.070 67 0.013 ± 0.002 0.066 ± 0.019 68 0.024 ± 0.028 0.591 ±0.256 69 0.015 ± 0.002 8.107 ± 1.147 70 0.012 ± 0.001 0.077 ± 0.001 710.335 ± 0.184 3.683 ± 0.285 72 0.290 ± 0.062 1.437 ± 0.304 73 0.069 ±0.013 0.415 ± 0.103 74 0.022 ± 0.002 0.055 ± 0.012 75 0.191 ± 0.0297.035 ± 0.710 76 0.029 ± 0.002 0.102 ± 0.117 77 0.176 ± 0.009 0.215 ±0.052 78 0.300 ± 0.035 4.379 ± 0.691 79 0.004 ± 0.001 0.336 ± 0.188 800.454 ± 0.040 0.356 ± 0.024 81 0.029 ± 0.002 0.083 ± 0.009 82 2.628 ±0.582 2.813 ± 0.089 83 0.019 ± 0.003 0.004 ± 0.002 84 0.010 ± 0.0020.622 ± 0.208 85 0.285 ± 0.041 0.402 ± 0.006 86 0.020 ± 0.015 3.360 ±0.286 87 0.328 ± 0.007 6.864 ± 0.798 88 0.714 ± 0.179 0.373 ± 0.117 890.056 ± 0.011 0.279 ± 0.044 90 0.508 ± 0.042 0.494 ± 0.081 91 0.421 ±0.044 0.150 ± 0.029 92 0.752 ± 0.033 3.327 ± 0.864 93 3.725 ± 0.357 >1094 1.829 ± 0.194 >10 95 2.238 ± 0.043 >10 96 0.792 ± 0.074 2.858 ± 0.98897 1.512 ± 0.802 >10

TABLE 4 Antiproliferative activity (72 h, GI₅₀ μM) of representativecompounds. Leukemia Ovarian Medulloblastoma Compound KG-1 MOLM-13 A2780D458 D283 9 0.047 ± 0.015 0.293 ± 0.028 — — — 29 — — 0.282 ± 0.058 0.326± 0.029 0.335 ± 0.097 31 — — 0.094 ± 0.001 0.645 ± 0.097 0.489 ± 0.02234 0.112 ± 0.045 0.408 ± 0.025 — — — 46 0.005 ± 0.004 0.098 ± 0.012 — —— 47 0.006 ± 0.001 0.076 ± 0.008 — — — 60 — — 0.081 ± 0.001 0.321 ±0.068 0.124 ± 0.020 64 — — 0.056 ± 0.007 0.457 ± 0.171 0.077 ± 0.006 86— — 0.072 ± 0.020 0.617 ± 0.112 0.358 ± 0.100

TABLE 5 Pharmacokinetic properties of representative compounds 60, 71,and 34 Compounds (po, 20 mg/kg in rat) Pharmacokinetic parameter 60^(a)71 71^(b) 34 Cmax (μM) 0.5 1.4 1.6 0.6 AUC (μM · hr) 6.6 15.9 5.9 10.2t_(1/2) (hr) 16.4 2.8 5.0 4.6 Oral bioavailability (F %) 51 27 100 39^(a)40 mg/kg in rat, ^(b)10 mg/kg in mice.

Throughout the specification and the claims that follow, unless thecontext requires otherwise, the words “comprise” and “include” andvariations such as “comprising” and “including” will be understood toimply the inclusion of a stated integer or group of integers, but notthe exclusion of any other integer or group of integers.

The reference to any prior art in this specification is not, and shouldnot be taken as, an acknowledgement of any form of suggestion that suchprior art forms part of the common general knowledge.

It will be appreciated by those skilled in the art that the invention isnot restricted in its use to the particular application described.Neither is the present invention restricted in its preferred embodimentwith regard to the particular elements and/or features described ordepicted herein. It will be appreciated that the invention is notlimited to the embodiment or embodiments disclosed, but is capable ofnumerous rearrangements, modifications and substitutions withoutdeparting from the scope of the invention as set forth and defined bythe following claims.

Please note that the following claims are provisional claims only, andare provided as examples of possible claims and are not intended tolimit the scope of what may be claimed in any future patent applicationsbased on the present application. Integers may be added to or omittedfrom the example claims at a later date so as to further define orre-define the invention.

1. (canceled)
 2. A compound of formula II:

wherein R¹ is selected from NH-methyl, NH-ethyl and NH-cyclopentyl; R²is C₁₋₆ alkyl; R³ is selected from the group consisting of H, halogenand CN; R⁴, R⁶ and R⁷ are each independently H; and R⁵ is selected fromthe following:

or a pharmaceutically acceptable salt, solvate or prodrug thereof
 3. Thecompound according to claim 2, wherein R¹ is NH-methyl orNH-cyclopentyl,
 4. (canceled)
 5. The compound according to claim 2,wherein R² is methyl.
 6. The compound according to claim 2, wherein R³is F. 7-16. (canceled)
 17. A method of treating cancer or anotherproliferative cell disease or condition in a subject, the methodcomprising administering to said subject a therapeutically effectiveamount of the compound of claim 2, optionally in combination with apharmaceutically acceptable carrier, diluent, excipient, or combinationthereof.
 18. The method of claim 17, wherein the proliferative celldisease or condition to be treated is selected from those characterisedby over-expression of CDK4, CDK6, or a combination thereof.
 19. Themethod of claim 18, wherein the proliferative cell disease or conditionto be treated is selected from the group consisting of biliary tractcancer, brain cancer, cancers of the central nervous system, breastcancer, cervical cancer, choriocarcinoma, colonic cancer, endometrialcancer, oesophageal cancer, gastric cancer, haematological neoplasms,intraepithelial neoplasms, liver cancer, lung cancer, lymphomas,neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostatecancer, colorectal cancer, sarcomas, skin cancer, testicular cancer,stromal tumours, germ cell tumours, thyroid, and renal cancer.
 20. Themethod of claim 18, wherein the proliferative cell disease or conditionto be treated is selected from the group consisting of acutelymphoblastic leukemia (ALL), acute myeloid leukaemia (AML), and chroniclymphocytic leukemia (CLL).
 21. (canceled)
 22. A pharmaceuticalcomposition or medicament comprising the compound of claim 2 and apharmaceutically acceptable carrier, diluent, excipient, or combinationthereof.
 23. (canceled)
 24. The compound according to claim 2, whereinthe compound is:4-(4-methyl-2-(methylamino)thiazol-5-yl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile,N-cyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-5-(5-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine,N-cyclopentyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-5-(5-fluoro-2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine,N-cyclopentyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine,5-(2-((5-(1,4-diazepan-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine,N-cyclopentyl-5-(2-((5-((4-ethylpiperazin-l-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amin,orN-cyclopentyl-5-(2-((5-((4-ethylpiperazin-l-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine.
 25. A pharmaceutical composition ormedicament comprising a compound selected from4-(4-methyl-2-(methylamino)thiazol-5-yl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine-5-carbonitrile,N-cyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-5-(5-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine,N-cyclopentyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine,N-cyclopentyl-5-(5-fluoro-2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine,N-cyclopentyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine,5-(2-((5-(1,4-diazepan-l-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N-cyclopentyl-4-methylthiazol-2-amine,N-cyclopentyl-5-(2-((5-((4-ethylpiperazin-l-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amin,andN-cyclopentyl-5-(2-((5-((4-ethylpiperazin-l-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine;and at least one pharmaceutically acceptable carrier, diluent orexcipient.
 26. A method according to claim 17, wherein said compound isadministered in combination with one or more additional agent(s) for thetreatment of cancer.
 27. A method according to claim 26, wherein theadditional agent(s) is selected from one or more of the followingcategories of anti-cancer agents; alkylating agents; antimetaboliteagents; antitumour antibiotics; antimitotic agents; and topoisomeraseinhibitors; anti-oestrogens; antiandrogens; LHRH antagonists andagonists; progestogens; aromatase inhibitors; and inhibitors of5α-reductase; c-Src kinase family inhibitors; metalloproteinaseinhibitors; inhibitors of urokinase plasminogen activator receptorfunction; and antibodies to heparanase; inhibitors of growth factorfunction; tyrosine kinase inhibitors; inhibitors of the hepatocytegrowth factor family; inhibitors of the insulin growth factor family;inhibitors of the platelet-derived growth factor family; inhibitors ofserine/threonine kinases; inhibitors of cell signalling through MEKand/or AKT kinases, c-kit inhibitors, abl kinase inhibitors,phosphoinositide-3-kinase (PI3K) inhibitors, Plt3 kinase inhibitors,CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor)kinase inhibitors; aurora kinase inhibitors; and cyclin dependent kinaseinhibitors; antiangiogenic agents; vascular damaging agents; andendothelin receptor antagonists.
 28. A method according to claim 27,wherein the additional agent(s) is selected from alkylating agents,antimetabolite agents and antimitotic agents.
 29. A method according toclaim 28, wherein the additional agent(s) is selected from5-fluoruracil, gemcitabine, temozolomide, cis-platin, oxaliplatin,carboplatin and taxoids.
 30. A method according to claim 29, wherein thecompound isN-cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine.31. A method according to claim 27, wherein the additional agent(s) isselected from inhibitors of cell signalling through MEK and/or AKTkinases, PI3 kinase inibitors and anti-oestrogens.